Inflammatory response to naturally occuring tiger snake envenomation in dogs, with a special emphasis on il-6 by Costet, Juliette
Open Archive TOULOUSE Archive Ouverte (OATAO)
OATAO is an open access repository that collects the work of Toulouse researchers and 
makes it freely available over the web where possible.
This is an author-deposited version published in : http://oatao.univ-toulouse.fr/
Eprints ID : 17534
To cite this version :
Costet, Juliette. Inflammatory response to naturally occuring tiger 
snake envenomation in dogs, with a special emphasis on il-6. 
Thèse d'exercice, Médecine vétérinaire, Ecole Nationale 
Vétérinaire de Toulouse - ENVT, 2016, 110 p.
Any correspondence concerning this service should be sent to the repository
administrator: staff-oatao@inp-toulouse.fr.
 
 
 
 
1. 
 
 
 
 
ANNEE 2016    THESE : 2016 – TOU 3 – 4081 
 
 
 
 
INFLAMMATORY RESPONSE TO NATURALLY 
OCCURRING TIGER SNAKE ENVENOMATION IN 
DOGS, WITH A SPECIAL EMPHASIS ON IL-6 
 
 
 
 
 
 
 
THESE 
pour obtenir le grade de 
DOCTEUR VETERINAIRE 
 
DIPLOME D’ETAT 
 
présentée et soutenue publiquement 
devant l’Université Paul-Sabatier de Toulouse 
COSTET Juliette 
Née, le 21 Août 1990 à Nice (06) 
 
 
 
 
Directeur de thèse : Mme Séverine BOULLIER 
 
 
 
 
 
 
 
PRESIDENT : 
Mme Bettina COUDERC 
 
DIRECTEUR DE THESE: 
Mme Séverine BOULLIER 
 
ASSESSEUR : 
M. Guillaume LE LOC’H 
 
MEMBRE INVITE : 
M. Manuel BOLLER 
 
JURY 
 
 
Professeur à l’Université Paul-Sabatier de TOULOUSE 
 
 
 
Maître de Conférences à l’Ecole Nationale Vétérinaire de TOULOUSE 
 
 
 
Maître de Conférences à l’Ecole Nationale Vétérinaire de TOULOUSE 
 
 
 
DACVECC from the University of Melbourne 
	  2	  
 
 
  
	   3	    
                                                                                                                  
 
Répartition des Enseignants-Chercheurs par Département. 
Mise à jour : 06/09/2016 
DIRECTRICE : ISABELLE CHMITELIN 
 
ELEVAGE ET PRODUITS/SANTE 
PUBLIQUE VETERINAIRE  
SCIENCES BIOLOGIQUES ET 
FONCTIONNELLES  
SCIENCES CLINIQUES DES ANIMAUX 
DE COMPAGNIE, DE SPORT ET DE 
LOISIRS 
 
Responsable : M. SANS 
 
ALIMENTATION  ANIMALE : 
M. ENJALBERT Francis, PR 
Mme PRIYMENKO Nathalie, MC 
Mme MEYNADIER Annabelle, MC  
 
EPIDEMIOLOGIE : 
Mathilde PAUL, MC 
 
MALADIES REGLEMENTEES-ZOONOSES-
MEDECINE PREVENTIVE DES 
CARNIVORES DOMESTIQUES-DROIT 
VETERINAIRE : 
M. PICAVET Dominique, PR 
 
 
PARASITOLOGIE-ZOOLOGIE : 
M. FRANC Michel, PR 
M. JACQUIET Philippe, PR 
M.     LIENARD Emmanuel, MC 
Mme BOUHSIRA Emilie, MC 
 
HYGIENE ET INDUSTRIE DES ALIMENTS : 
M. BRUGERE Hubert, PR 
M. BAILLY Jean-Denis, PR 
Mme BIBBAL Delphine, MC 
Mme  COSTES Laura, AERC 
Mme  DAVID Laure, MCC 
 
PATHOLOGIE DE LA REPRODUCTION : 
M. BERTHELOT Xavier, PR 
M. BERGONIER Dominique, MC 
Mme CHASTANT-MAILLARD Sylvie, PR 
Mme HAGEN-PICARD Nicole, PR 
M NOUVEL Laurent-Xavier, MC  
Mme MILA Hanna, MC 
 
PATHOLOGIE DES RUMINANTS : 
M.     SCHELCHER François, PR 
M. FOUCRAS Gilles, PR 
M      CORBIERE Fabien, MC 
M.     MAILLARD Renaud, MC 
M. M.     MEYER Gilles, PR 
 
PRODUCTION ET PATHOLOGIE AVIAIRE 
ET PORCINE : 
Mme WARET-SZKUTA Agnès, MC 
M. JOUGLAR Jean-Yves, MC 
M.     GUERIN Jean-Luc, PR 
M.     LE LOC’H Guillaume, MC 
 
 
PRODUCTIONS ANIMALES 
AMELIORATION GENETIQUE ECONOMIE : 
M. DUCOS Alain, PR 
M. SANS Pierre, PR 
M.      RABOISSON Didier, MC 
 
 
Responsable : Mme GAYRARD 
 
 
 
ANATOMIE : 
M. MOGICATO Giovanni, MC 
M.     LIGNEREUX Yves, PR 
Mme DEVIERS Alexandra, MC 
 
 
ANATOMIE PATHOLOGIQUE - HISTOLOGIE : 
M. DELVERDIER Maxence, PR 
Mme LETRON-RAYMOND Isabelle, MC 
Mme BOURGES-ABELLA Nathalie, PR 
Mme LACROUX Caroline, PR 
 
 
BIOLOGIE MOLECULAIRE : 
Mme  BOUCLAINVILLE-CAMUS Christelle, MC 
 
MICROBIOLOGIE – IMMUNOLOGIE - 
MALADIES INFECTIEUSES : 
M.      MILON Alain, PR 
M. BERTAGNOLI Stéphane, PR 
M. VOLMER Romain, MC  
Mme BOULLIER Séverine, MC 
Mme DANIELS Hélène, MC 
 
 
BIOSTATISTIQUES : 
M. CONCORDET Didier, PR 
M. LYAZRHI Faouzi, MC 
 
 
PHARMACIE-TOXICOLOGIE : 
M. PETIT Claude, PR 
Mme CLAUW Martine, PR 
M. GUERRE Philippe, PR 
M. JAEG Philippe, MC 
 
PHYSIOLOGIE –PHARMACOLOGIE 
THERAPEUTIQUE : 
M.  BOUSQUET-MELOU Alain, PR 
Mme  GAYRARD-TROY Véronique, PR 
Mme   FERRAN Aude, MC 
M.  LEFEBVRE Hervé, PR 
 
BIOCHIMIE. : 
Mme BENNIS-BRET Lydie, MC 
 
ANGLAIS : 
M. SEVERAC Benoît, PLPA 
Mme MICHAUD Françoise, PCEA 
 
 
 
 
 
Responsable : Mme CADIERGUES 
 
 
 
ANESTHESIOLOGIE 
M. VERWAERDE Patrick, MC 
 
CHIRURGIE : 
M. AUTEFAGE André, PR 
M. ASIMUS Erik, MC 
M. MATHON Didier, MC 
Mme MEYNAUD-COLLARD Patricia, MC 
Mme PALIERNE Sophie, MC 
 
MEDECINE INTERNE : 
Mme DIQUELOU Armelle, MC 
M. DOSSIN Olivier, MC 
Mme LAVOUE Rachel, MC 
Mme GAILLARD-THOMAS Elodie, MCC 
 
OPHTALMOLOGIE : 
M.      DOUET Jean-Yves, MC 
 
 
DERMATOLOGIE : 
Mme CADIERGUES Marie-Christine, PR 
 
 
IMAGERIE MEDICALE 
M. CONCHOU Fabrice, MC 
 
BIOLOGIE MOLECULAIRE. : 
Mme  TRUMEL Catherine, PR 
 
PATHOLOGIE DES EQUIDES : 
M.     CUEVAS RAMOS Gabriel, MC 
Mme   PRADIER Sophie, MC 
Mme LALLEMAND Elodie, AERC 
 
 
	  4	  
  
	   5	  
Remerciements / Acknowledgements 
 
 
 
A la président du jury, Madame le Professeur Bettina Couderc, 
 
Professeur des Universités, 
 
Pour m’avoir fait l’honneur d’accepter la présidence du jury de thèse, je vous prie de croire, 
Madame, en ma sincère gratitude. 
 
 
 
 
To the inviting staff member, Dr. Manuel Boller 
 
Dipl. ACVECC, 
 
Thank you for letting me take part in this research project, for your time, your support and your 
help in my work. Thank you for your kindness and your generosity. You made me feel 
welcome from the very beginning and it was a great experience working with you on this 
project. 
 
  
 
 
A la directrice de thèse, Madame le Docteur Séverine Boullier, 
 
Maître de conférences à l’Ecole Nationale Vétérinaire de Toulouse, 
 
Pour votre accompagnement au cours de cette thèse et pour m’avoir fait l’honneur de participer 
à ce jury de thèse, veuillez accepter mes sincères remerciements. 
 
 
 
 
A l’assesseur, Monsieur le Docteur Guillaume Le Loch, 
 
Maître de conférences à l’Ecole Nationale Vétérinaire de Toulouse, 
Nouveaux animaux de compagnie, 
 
Pour m’avoir fait l’honneur de participer à ce jury de thèse, veuillez accepter mes sincères 
remerciements. 
 
 
 
 
 
 
 
 
 
	  6	  
To the team involved in the study, 
 
 
 
To Monique Stanley, 
 
Thank you for your help with the research project. It was very nice to work with you. 
 
 
 
A Julien Dandrieux, 
 
Pour m'avoir accompagné dans la réalisation des manipulations, pour votre aide précieuse et 
votre sympathie, veuillez accepter toute ma gratitude. 
 
 
 
To the Intensive Care Unit, 
 
I am very grateful to all of you for your kindness and your help in collecting samples. 
. 
 
  
	   7	  
TABLE OF CONTENTS 
 
INDEX OF ILLUSTRATIONS....................................................................................................9 
INDEX OF ABBREVIATIONS.................................................................................................13 
INTRODUCTION.......................................................................................................................15 
1. PART 1. BIBLIOGRAPHIC STUDY ON SNAKE ENVENOMATION ................................. 17 
 
1.1 GENERALITIES ON SNAKE ENVENOMATION .................................................................. 17 
 
1.1.1 DEFINITION OF SNAKE ENVENOMATION AND TIGER SNAKE GROUP OVERVIEW
 ............................................................................................................................................17 
 
1.1.2 PRINCIPAL COMPONENTS OF SNAKE VENOM ......................................................... 23 
 
1.1.2.1 Venom neurotoxins ....................................................................................................................................... 23 
1.1.2.2 Venom components acting on the hemostatic system ................................................................................... 25 
 
1.1.2.2.1 Venom proteins acting on blood coagulation factors ........................................................................... 25 
1.1.2.2.2 Venom proteins acting on vessel walls ................................................................................................. 27 
1.1.2.2.3 Venom proteins acting on platelets ....................................................................................................... 27 
 
1.1.2.3 Lipases ........................................................................................................................................................... 28 
1.1.2.4 Venom component specific to Elapid snakes ................................................................................................ 29 
 
1.1.3 CLINICAL PRESENTATION OF SNAKE ENVENOMATION IN DOGS ........................ 30 
 
1.1.4 CLINICOPATHOLOGICAL VARIABLES ASSOCIATED WITH OPHIDIAN 
ENVENOMATION ........................................................................................................................ 34 
 
1.1.4.1 Biochemistry ................................................................................................................................................. 34 
 
1.1.4.2 Heamatology markers ................................................................................................................................... 36 
1.1.4.2.1 RBC abnormalities ................................................................................................................................ 36 
1.1.4.2.2 Leukocytes abnormalities ..................................................................................................................... 36 
 
1.1.4.3 Hemostatic changes ....................................................................................................................................... 37 
1.1.4.3.1 Platelets abnormalities .......................................................................................................................... 37 
1.1.4.3.2 Vascular abnormalities: coagulopathy .................................................................................................. 37 
 
1.1.5 DIAGNOSIS OF SNAKE BITES ....................................................................................... 39 
1.1.5.1 History ........................................................................................................................................................... 40 
1.1.5.2 Clinical evidence ........................................................................................................................................... 40 
1.1.5.3 Laboratory tests ............................................................................................................................................. 40 
1.1.5.4 Snake venom detection kit (SVDK) .............................................................................................................. 41 
 
1.1.6 TREATMENT .................................................................................................................... 43 
1.1.6.1 First aid treatment .......................................................................................................................................... 43 
1.1.6.2 Antivenom treatment ..................................................................................................................................... 43 
1.1.6.3 Prophylactic treatment and symptomatic supportive treatment .................................................................... 46 
 
1.1.7 PROGNOSIS ..................................................................................................................... 47 
 
1.2 IMMUNE RESPONSE AFTER ENVENOMATION ................................................................ 49 
 
1.2.1 IMMUNE SYSTEM: OVERVIEW ..................................................................................... 49 
 
1.2.2 MAIN CARACTERISTICS OF THE INFLAMMATORY RESPONSE .............................. 50 
 
1.2.2.1 Acute inflammation ....................................................................................................................................... 51 
1.2.2.2 Chronic inflammation ................................................................................................................................... 51 
1.2.2.3 Complement system ...................................................................................................................................... 52 
1.2.2.4 Involvement of cytokines in acute inflammatory responses ......................................................................... 54 
	  8	  
 
1.2.2.4.1 Cytokine overview ................................................................................................................................ 54 
1.2.2.4.2 Multifunctional cytokines ..................................................................................................................... 54 
1.2.2.4.3 Cytokines and acute Phase Protein synthesis ........................................................................................ 56 
1.2.2.4.4 Cytokines and recruitment of leukocytes to inflammatory sites ........................................................... 56 
1.2.2.4.5 Role of cytokines, neutrophil activity and neutrophil apoptosis: protective or deleterious 
inflammatory response ............................................................................................................................................. 57 
1.2.2.4.6 Fever induction ..................................................................................................................................... 60 
 
1.2.2.5 Interleukin-6: principal characteristics and interests ..................................................................................... 61 
1.2.2.5.1 Pro and anti-inflammatory activities, hematopoiesis activity ............................................................... 61 
1.2.2.5.2 Interleukin-6: beneficial and deleterious effects ................................................................................... 62 
1.2.2.5.3 Interleukin-6: cytokine measurement in body fluids ............................................................................ 64 
1.2.2.5.4 Interleukin-6: interests of investigation ................................................................................................ 65 
 
1.2.3 IMMUNE SYSTEMIC RESPONSE TOWARDS SNAKE VENOM .................................... 66 
 
1.2.3.1 Evidence and mechanisms of inflammation induced in snake envenomation .............................................. 66 
 
1.2.3.1.1 Oedema ................................................................................................................................................. 66 
1.2.3.1.2 Influx of leucocytes ............................................................................................................................... 66 
1.2.3.1.3 Inflammatory mediators ........................................................................................................................ 67 
 
1.2.3.2 Venom components acting in the inflammatory response ............................................................................ 69 
 
1.2.3.3 Venom components and inflammation in Elapids ........................................................................................ 73 
 
1.2.3.4 Neutralization of the systemic inflammatory response by current treatment ................................................ 73 
 
2. PART 2. EXPERIMENTAL PROTOCOL, RESULTS AND DISCUSSION ......................... 75 
 
2.1. OBJECTIVES AND HYPOTHESIS .......................................................................................... 75 
 
2.2. MATERIAL AND METHODS .................................................................................................. 75 
 
2.2.1. POPULATION: INCLUSION CRITERIA ......................................................................... 75 
2.2.2. GENERAL DATA .............................................................................................................. 76 
2.2.3. CLINICOPATHOLOGICAL DATA .................................................................................. 77 
2.2.4. INFLAMMATORY MARKERS MEASUREMENTS: IL-6 LEVELS .................................. 77 
2.2.5. STATISTICS ...................................................................................................................... 78 
 
2.3. RESULTS .................................................................................................................................. 78 
 
2.3.1. DOGS AND SNAKEBITE INFORMATION ...................................................................... 78 
2.3.2. CLINICAL FINDINGS ...................................................................................................... 79 
2.3.3. BICHEMISTRY, HAEMATOLOGY AND CELL BLOOD COUNT, COAGULATION TIMES
 ............................................................................................................................................80 
2.3.4. DIAGNOSIS OF SNAKE ENVENOMATION ................................................................... 82 
2.3.5. KINETIC FOLLOW-UP OF IL-6 ..................................................................................... 83 
2.3.6. TREATMENT AND OUTCOME ....................................................................................... 86 
 
2.4. DISCUSSION ................................................................................................................................ 87 
 
2.4.1. THE INFLAMMATORY RESPONSE ................................................................................ 87 
2.4.2. CLINICAL AND CLINICOPATHOLOGICAL FEATURES ............................................. 92 
2.4.3. LIMITATIONS ................................................................................................................... 95 
 
2.5. CONCLUSION .............................................................................................................................. 97 
   
BIBLIOGRAPHY.......................................................................................................................99 
	   9	  
INDEX OF ILLUSTRATIONS 
Figures:  
 
Figure I. Venom apparatus of Russell’s viper: dissected snake (A), annotated diagram (B) 
(Warrell 2010) ..................................................................................................................... 18 
 
Figure II. Map of the distribution of the tiger snake, 2,366 records  (Hardy, Cochrane, Allavena 
2014). .................................................................................................................................. 20 
 
Figure III. Site of action of presynaptic and postsynaptic snake venom neurotoxins (Van den 
Enden MD, Erwin. 2015). ................................................................................................... 24 
 
Figure IV. Site of action of venom proteins on the cascade of haemostasis (Lu, Clemetson, 
Clemetson 2005, p1792). .................................................................................................... 26 
 
Figure V. Snake venom detection kit: correspondence of wells and snakes immunotypes and 
antivenom indicated (SVDK, manufacturer data) .............................................................. 42 
 
Figure VI. The innate and adaptive system (Day Michael J, Veterinary Immunology book, p11, 
2011) ................................................................................................................................... 50 
 
Figure VII. The four complement pathways and their interaction (Day Michael J., Veterinary 
Immunology book, p31, 2011) ............................................................................................ 52 
 
Figure VIII. Roles of complement factors C3a and C5a (Day Michael J, Veterinary 
Immunology book, p35, 2011) ............................................................................................ 53 
 
Figure IX. Leukocytes adhesion and involvement of chemokines (Day Michael J, Veterinary 
Immunology book, p63, 2011) ............................................................................................ 57 
 
Figure X. Inflammatory response and role of neutrophils (Simon 2003). .................................. 59 
 
Figure XI. Example of cytokine storm and deleterious inflammation in a case of pneumonia 
(Bordon et al. 2013) ............................................................................................................ 59 
 
Figure XII. Summary of numerous activities of IL-1, IL-6 and TNF and interaction between 
cytokines (modified from Paul William E., p656, 1989). ................................................... 60 
 
Figure XIII. Implication of IL-6 in the transition from neutrophil to monocyte recruitment 
(Kaplanski et al. 2003) ........................................................................................................ 62 
 
Figure XIV. Main activities of IL-6. Simplified figure of beneficial versus deleterious effects of 
IL-6. .................................................................................................................................... 63 
 
Figure XV. Factors affecting cytokine measurement in body fluids (Bienvenu et al. 2000). .... 64 
 
Figure XVI. Effects of snake venom on the production and the activation of mediators 
(modified from Luna, da Silva, and Pereira 2011). ............................................................ 69 
 
Figure XVII. Metalloproteinases and their roles in the pathogenesis of local tissue damage 
(Rucavado et al. 2002) ........................................................................................................ 70 
	  10	  
 
Figure XVIII. Schematic summary of the inflammatory action of a metalloproteinases and 
phospholipases A2 of Bothrops asper venom (C. Teixeira et al. 2009) ............................. 72 
 
 
Tables:  
 
Table I. Geographical distribution of snakebites (Mirtschin et al. 1998) ................................... 21 
 
Table II. Distribution of snakebites in Australia in relation to species (Mirtschin et al. 1998). . 22 
 
Table III. Summary of principal types of toxin effects on the haemostatic system (modified 
from Francis S. Markland 1998). ........................................................................................ 28 
 
Table IV. Venom protein components of Elapid snake species and their main effects on the 
organism (modified from Birrell et al. 2007) ...................................................................... 30 
 
Table V. Clinical presentation of snake envenomation .............................................................. 33 
 
Table VI. Laboratory evidences of snake envenomation ............................................................ 39 
 
Table VII. List of monovalent antivenoms available from CSL and corresponding snake 
venoms neutralised (modified from SVDK, manufacturer data) ........................................ 44 
 
Table VIII. Properties of IL-1, IL-6 and TNF-alpha (from Akira et al. 1990) ........................... 55 
 
Table IX. Signalment and history ............................................................................................... 79 
 
Table X. Laboratory diagnosis: biochemistry ............................................................................. 80 
 
Table XI. Laboratory diagnosis: electrolytes .............................................................................. 81 
 
Table XII. Laboratory diagnosis: cell counts .............................................................................. 81 
 
Table XIII. Laboratory diagnosis: acid base status ..................................................................... 81 
 
Table XIV. Major criteria for laboratory diagnosis of envenomation ........................................ 82 
 
 
  
	   11	  
 
Graphics: 
 
Graphic 1. Mean, median and quartile of IL-6 levels for each time in affected and healthy dogs
 ............................................................................................................................................. 84 
 
Graphic 2. Evolution of mean IL-6 levels depending on time post admisison ........................... 85 
 
Graphic 3. Evolution of IL-6 levels for each dog ....................................................................... 85 
 
 
Diagrams: 
 
Diagram 1.Taxonomy of most venomous snake snakes. Focus on snakes observed in Australia 
(modified from Harris 1985; White, 2013). ........................................................................ 17 
 
Diagram 2.  Key steps for snakebite diagnosis ........................................................................... 40 
 
Diagram 3. Clinical signs present at the admission (on 10 dogs) ............................................... 79 
 
 
Photographs:  
 
Photograph 1. Common tiger snake (Notechis scutatus) (personal picture) ............................... 19 
 
Photograph 2. Eastern Brown Snake (Pseudonaja textilis)  (from Queensland museum website)
 ............................................................................................................................................. 19 
 
 
 
 
 
 
 
 
	  12	  
  
	   13	  
 
INDEX OF ABBREVIATIONS 	  
APP = Acute Phase Proteins  
ACPs = Antigen Presenting Cells  
aPTT = activated Partial Thromboplastin Time 
ALT = Alanine Amino Transferase 
ALKP = Alkaline Phosphatase 
APPs = acute phase proteins  
BR = Breath Rate 
CK = Creatine Kinase 
COX = Cyclooxygenases  
CRP = C-Reactive Protein  
DIC = Disseminated Intravascular Coagulopathy 
F. V, VIII, IX, X, XII= Factor V, VIII, IX, X, XII 
FPD = Fibrinogen Product Degradation 
GLDH = G- Lactate Deshydrogenase 
HR = Heart Rate 
ICAM-1 = intercellular adhesion molecule 1 
IL-1,6,8, etc. =  Interleukin 1, 6, 8, etc . 
INF-γ = Interferon γ 
iNOS = Inducible Nitric Oxide Synthetase 
INR = International Normalized Rates 
LTE = Leukotriene E 
MCP-1 = Monocyte Chemoattractant Protein-1 
NK = Natural killer 
NO = Nitric Oxide 
PECAM-1 = Platelet Endothelial Cell Adhesion Molecule 1  
PGE = Prostaglandins E 
PLA2 = Phosphatidylcholine 2- Acylhydrolase (phospholipase A2) 
PLT = Platelets 
PMN = Polymorphonuclear	  Neutrophils 
PT = Prothrombine Time  
RANTES = Regulated on Activation Normal T cell Expressed and Secreted  
RBC = Red Blood Cell 
RT-PCR = Real-Time Reverse Transcriptase-Polymease Chain Reaction  
SAA = Serum Amyloid A  
SVDK = Snake Venom Detection Kit 
SVMP = Snake Venom Metalloproteinases 
TNF-α = Tumor Necrosis Factor α 
TGF-β = Transforming Growth Factors β 
T. snake = Tiger snake 
TXA2 = Thromboxane A2 
VICC = Venom Induced Consumption Coagulopathy 
WBC = White Blood Cells 
	  14	  
  
	   15	  
INTRODUCTION 
 
Venomous snakes are widespread in the world and Australia is home to many of them.  
The systematic classification of snakes recognises between 11 and 13 distinct families. 
Venomous snakes are identified in only 5 families: Elapidae, Hydrophiidae, Viperidae, 
Crotalidae and Colubridae (Order Squamata, class Reptilia) (Harris 1985). The genus Notechis 
belong to the family Elapidae, restricted to the wettest part of Southern and Eastern Australia. 
The species Notechus scutatus (also called tiger snake) presents variable morphs with different 
sizes and colourations that some authors recognise as several subspecies while others recognise 
Notechis as a monotypic genus (Shea 2000). 
 
Due to their high activity, dogs are particularly subject to be bitten and consequently 
snake envenomation is a common emergency in this species. It has been estimated that more 
than 6000 snake envenomed dogs are presented to veterinary clinics in Australia each year 
(Mirtschin et al. 1998). Tiger snake (Notechis scutatus) and eastern brown snake (Pseudonaja 
textilis), both of them from the Elapidae family, were found to be the most commonly 
implicated (White 1998, Mirtschin et al. 1998). If brown snakes are more often incriminated 
within Australia, tiger snakes are definitely the most commonly encountered species implicated 
in dog snake envenomation in the state of Victoria (Mirtschin et al. 1998) and thus represent a 
major threat to the health of humans and pets in this area. 
Snake venoms are complex cocktails of toxins, containing numerous peptides, proteins 
and salts. These venom components act as neurotoxins, myotoxins, cardiotoxins and 
modulators of coagulation and inflammation (Fry 1999, Goddard et al. 2011). Tiger snakes are 
one of the world’s most venomous snakes based on their venom LD50 and because of their 
notexins – including the main neurotoxic phospholipase A2 (PLA2) and snake venom 
metalloproteinases (SVMP), which are important components of Elapids snake venom (Cher et 
al. 2003, Birrell et al. 2007).  
Dogs envenomed by tiger snakes typically have mydriasis, decreased or absent 
pupillary light reflexes, depressed mentation, generalised muscle weakness, ataxia, tachypnoea 
or dyspnoea, vomiting and salivation (Hill 1979; Barr 1984). These clinical abnormalities, 
associated with the history, as well as laboratory test findings such as prolonged coagulation 
times, elevated serum creatine kinase and snake venom detection test, lead to the diagnosis of 
snake envenomation (Heller et al. 2007). 
The evidence of an inflammatory response to snake envenomation, characterized by 
oedema, inflammatory cell infiltrate, and changes in inflammatory mediators levels, has been 
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reported in several studies (Gutiérrez et al. 1995, Picolo et al. 2002, Moreira et al. 2012, 
Escocard et al. 2006) and represents the major part of the “post envenomation syndrome”. It 
was specifically described for vipers (Bothrops asper, Vipera russelli, Ammodytes, 
Meridionalis, Aspis), rattlelsnakes (Crotalus) and Elapids (Maria Fernandes et al., 2006, 
Zamuner et al., 2005, Langhorn et al., 2014, Santhosh et al., 2013, Szold et al., 2001, 
Tambourgi et al., 1994). Increased pro-inflammatory cytokines levels (e.g. interleukine IL-6, 
neutrophil attracting chemokine IL-8, the chemokine monocyte chemoattractant protein-1 
MCP-1), induced by PLA2 and SVMP are implicated in these inflammatory processes 
(Rucavado et al. 2002, Moreira et al. 2012). 
Out of the pro- inflammatory cytokines, interleukin-6 (IL-6) is one of the major 
mediators of acute phase proteins (APPs) synthesis in the liver (Murata, Shimada, Yoshioka 
2004). IL-6 is induced by macrophages and other various cells, and is further amplified by IL-1 
and TNFα. In dogs, its concentration markedly increases after inflammation stimulation 
(Yamashita et al. 1994) and therefore can be used for quantifying the induced systemic 
response to inflammation (Cerón, Eckersall, Martínez-Subiela 2005). 
Antivenom is formulated from the plasma of horses immunised with the venom of snakes 
(hyperimmune IgG serum) (CSL, 2014). It is the current standard treatment that efficiently 
improves the main threatening systemic effects such as coagulopathy resulting from 
envenoming (MacDonald, White, Currie 2008). Nevertheless, its use seems to be partially 
inefficient against local manifestation induced by the inflammatory response to Viperidae 
snake envenomation (Araújo et al. 2007, Picolo et al. 2002, J. M. Gutiérrez 1981, Chaves, 
Barboza, Gutiérrez 1995). It was even found to further exacerbate the venom induced immune 
response and brings a second pro-inflammatory hit (León et al. 2013, Stone et al. 2013).  
However, even though tiger snakebites hundreds of dogs every year in Australia, its impact on 
inflammation has not been examined. That is why there is a real need for understanding the 
mechanism and characteristics of the post-envenomation syndrome that follow after initial 
obvious crisis. While the relative contribution of inflammatory processes to the overall clinical 
picture remains insufficiently described at this time, their attenuation may be exploited as an 
exciting new therapeutic avenue and clinical trials using immune-modulatory drugs could be 
warranted. 
 
The aim of this prospective study was to examine the systemic inflammatory response 
associated with snake envenomation and antivenom administration in dogs, with a special 
emphasis on IL-6.  
 
	   17	  
2. PART 1. BIBLIOGRAPHIC STUDY ON SNAKE 
ENVENOMATION 
 
1.1 GENERALITIES ON SNAKE ENVENOMATION 
 
1.1.1 DEFINITION OF SNAKE ENVENOMATION AND TIGER SNAKE 
GROUP OVERVIEW 
 
Definition: 
Envenoming is the process where venom is introduced into a human being or an animal, 
and generally refers to the situation where enough venom is introduced to cause clinical effects. 
Snake venom can be defined as highly modified saliva able to immobilize and digest the prey 
by means of the actions of protein-degrading enzymes (Goddard et al. 2011; J. White, 2013). 
 
Taxonomy of tiger snakes 
Five venomous snake families are recognized: Elapidea, Hydrophiidae, Viperidae, 
Crotalidae and Colubridae (Diag. 1). The Hydrophiidae family includes sea snakes and is 
considered by some as a sub-family or family of the Elapidae. Crotalidae is considered by some 
as a sub-family of the Viperidae (Harris 1985).  
 
 
 
Diagram 1.Taxonomy of most venomous snake snakes. Focus on snakes observed in Australia 
(modified from Harris 1985; White, 2013).  
Class Reptilia, 
Order 
Squamata 
Elapidae 
Observed in Australia: tiger snakes (genus 
Notechis), brown snakes (Pseudonaja), common 
copperhead (Austrelaps), taipan (Oxyuranus), death 
adder (Acanthophis), mulga  and red bellied black 
snake (Pseudochis)	  
No native or rarely observed                                                
king cobra (Ophiophagus), Mamba (Dendroaspis), 
rough scales snakes (Tropedichis) 
Hydrophiidae Also considered as Elapidae, include snakes in marine environment 
Viperidae No native in Australia (Genus Bothrops, Vipera) 
Crotalidae No native: Rattlesnake (Genus Crotalus)                 Also considered as a Viperidae 
Colubridae Aquatic or semi aquatic snakes 
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Most of the research on the Elapidae family was focused on five major groups: brown 
snakes (genus Pseudonaja), tiger snakes (genus Notechis), black snakes (genus Pseudechis), 
death adders (genus Acanthophis) and taipans (genus Oxyuranus) (Hodgson and 
Wickramaratna 2006). Tiger snakes (Notechis scutatus) belong to the Elapidae family. 
 
Description and identification of tiger snakes 
Venomous snakes use fangs to inject their venom (Fig.I). 
 
Figure I. Venom apparatus of Russell’s viper: dissected snake (A), annotated diagram (B) 
(Warrell 2010)  
The venom is stored in the venom gland; the activation of muscularis compressor 
glandulae allows venom ejection through the venom duct until the fangs. 
 
Tiger snakes are, as all Elapid snakes, proteroglyphous carnivorous snakes, ie. snakes 
with permanently erect poisonous fangs at the front of the maxilla (Meier J. et al. 1995). Fangs 
of adult tiger snakes are about 3.5mm long and produce a moderate amount of very toxic 
venom.  
Tiger snakes have an average length between 1.2m to 1.5m according to the authors. 
Colouration can vary from the classical banded dark grey/black and yellow skin to unbanded 
types with a range of colors from black to light grey (Geoffrey K. Isbister et al. 2012). Most of 
tiger snake species show some bands but unbanded species exist too (Shea 2000).  As 
colouration and banding vary, brown snakes can be easily confused with tiger snakes 
(Photographies 1, 2). 
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Photograph 1. Common tiger snake (Notechis scutatus) (personal picture) 
 
 
       
Photograph 2. Eastern Brown Snake (Pseudonaja textilis)  (from Queensland museum 
website) 
A study on the ability of Australians to recognize snake species has shown that 
identification is highly inaccurate (Morrison, Pearn, Covacevich, et al. 1983). In this study 
composed of 558 volunteers, only 19% of snakes were correctly identified, which includes the 
identification of 18% of tiger snakes only. Subjects who grew up in rural areas seem to be 
better at identifying snakes. It seems that the misidentification is due to a combination of 
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factors, including inconsistent common nomenclature and similarities in appearance for 
different snake species.  
The most reliable method of snake species’ identification is scale counting but it requires 
the snake to be dead at the time of the examination. Tiger snakes can be most readily 
differentiated from other snakes by the combination of a broad parietal scale - as wide as long, 
but shorter than the temporolabial scale and unpaired subcaudal scales (Shea 2000). Some 
authors have used a combination of detailed appearance and scalation for classification (Heller 
et al. 2007).  
 
Geographic range, habitat and ecology: 
The three most commonly encountered snakes causing envenomation of veterinary 
importance in Australia are the brown snake, the tiger snake, and the red-bellied black snake, 
from the Elapidae family (Hardy, Cochrane, Allavena 2014).   
.  
Figure II. Map of the distribution of the tiger snake, 2,366 records  (Hardy, Cochrane, 
Allavena 2014).   
It indicates the relative density of this species in Australia: tiger snakes are mainly 
concentrated along the South coast, especially along the South - East coast. 
 
Tiger snakes are especially distributed near the coast, in Eastern, Southern and Western 
Australian waters. Fig.II indicates the relative density of this species in Australia. They are also 
found in Bass Strait Islands and Tasmania. This species is found near water areas such as 
riparian woodlands and watercourses, and eat amphibians and birds (IUCN 2009). 
 
Epidemiology aspects of snake envenomation in dogs 
The snakebite in domestic animals is frequent, with an average of four cases per year 
presented to each veterinary clinic and a total of about 6,240 cases reported annually. Moreover 
these numbers are probably underestimated because of the number of animals bitten but not 
treated, like those who survived alone and those who died before having been brought to a 
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clinic (Mirtschin et al. 1998). Tiger snakes, genus Notechis, are a common cause of snakebites 
and the second most common cause of snakebite deaths in humans in Australia (J. White, 
2013).  
A study describes some epidemiology aspects of 125 dogs envenomation enrolled in the 
Melbourne university hospital in Werribee. In this study, 77% of the dogs (n=125) were 
sporting breeds, around 4.1 years old with 40% being 2 years old or younger. 48% of the dogs 
were seen bitten by a snake, almost all by a tiger snake (only one case was a brown snake 
identified). The highest number of snakebite’ occurences in dogs occurred in December and 
January (50%), when the temperature rises to around 20°C or above (Barr 1984). 
 
To determine the extent of the snakebite problem in domestic animals, a study was made 
based on a questionnaire sent to 10% of veterinary surgeons, selected randomly throughout 
Australia. Queensland was the region where most of snakebite cases were recorded (Tabl.I) 
over a 5-year period (413 dogs), followed by Victoria (88 dogs) and New South Wales 
(87dogs) (Mirtschin et al. 1998). 
 
Table I. Geographical distribution of snakebites (Mirtschin et al. 1998) 
 
Most of snakebites in dogs occurred in Queensland (413 dogs), Victoria (88 dogs) and 
New South Wales (87 dogs). Considering all animals, the total number of snakebites that 
occurred in Queensland is three times more important than in any other states. 
QLD= Queensland, NSW= New South Whales, SA= South Australia, Vic= Victoria, 
WA= Western Australia, Tas= Tasmania, ACT Australian Capital territory, NT= Northern 
territory. Not known= address non-indicated by respondents, Other= Wallaby, Kangaroo and 
two unidentified animals. 
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In Victoria and Tasmania, more than half of dogs were bitten by tiger snakes (121 dogs), 
while in the other states, brown snakes were more often incriminated (Tabl. II). 
 
Table II. Distribution of snakebites in Australia in relation to species (Mirtschin et al. 1998). 
   
Different proportion of snake species are implied in snakebites depending on the state 
considered. Dogs have been bitten in majority by tiger snakes in Victoria whereas brown 
snakes are more frequently involved in other states. 
QLD= Queensland, NSW= New South Whales, SA= South Australia, Vic= Victoria, 
WA= Western Australia, Tas= Tasmania, ACT Australian Capital territory, NT= Northern 
territory. Not known= address non-indicated by respondents 
 
Bites have also been shown to be more prominent in rural areas (78%) compared to urban 
areas (22%) with brown, tiger and black snakes accounting for 76%, 13% and 6% of cases, 
respectively (Mirtschin et al. 1998). 
 
Venom toxicity  
The tiger snake is one of the world’s most venomous snakes based on its venom Lethal 
Dose 50% (LD50= 0,118mg/Kg) (4th venomous species with the lower LD50) (Broad, 
Sutherland, and Coulter 1979). Nevertheless, to assess the relative danger of each snake 
species, many other factors such as the relative toxicity should be taken into consideration. The 
amount of venom injected into the prey and the ‘efficiency’ of the bite (i.e. the masse of venom 
actually injected into tissues) are of great importance. They have been shown to depend on the 
number of consecutive bites, fang length and oral morphology, posture and ferocity in attack or 
defense. The age of the snake may influence the relative toxicity: for example, decreased 
coagulant activity has been reported with increasing age (Chippaux, Williams, and White 1991; 
Heller et al. 2007; Morrison et al. 1983). Dogs seem to be particularly sensitive, with lethal 
doses reported of 0,03mg/Kg, making them three times more sensitive than cats (Barr 1984).   
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1.1.2 PRINCIPAL COMPONENTS OF SNAKE VENOM 	  
Snake venoms are the most complex of all natural venoms and poisons. They contain a 
large number of toxic and non-toxic proteins and peptides, non-protein toxins, carbohydrates, 
lipids, amines, and other small molecules. These components allow to digest the prey, to 
paralyse it or to kill it.  Under evolutionary pressures, venoms have evolved to take full 
advantage of ecological niches and prey species. Venom toxins have been selected to be 
specific for many targets in animal tissue (Warrell 2010; Goddard et al. 2011). 
 
The tiger snake venom contains potent neurotoxins (nerve damaging, pre- and post-
synaptic toxins), myotoxins and modulators of coagulation and inflammation. Neurotoxic 
components affect the central nervous system by blocking neurotransmission. Myotoxins lead 
to severe muscle damage. Venom constituents are also able to disrupt the haemostatic system 
by affecting blood coagulation (procoagulant and anticoagulant components, fibrino(geno)lytic 
components), by acting on vessel walls and by acting on platelets (aggregating agents and 
aggregating inhibitors agents) (Tabl.III).  
 
Three main types of venom components have been characterised from Australian Elapids, 
family in which tiger snake belongs: powerful peptidic neurotoxins, proteins acting on the 
hemostatic system and lipases (Fry 1999; Goddard et al. 2011).  
 
1.1.2.1 Venom neurotoxins 
 
The neurotoxic components of Elapid snake venom may act either pre or post synaptic at 
the neuromuscular junction to disrupt nervous function.  
 
Pre-synaptic action (β-neurotoxins) 
Presynaptic neurotoxins have been identified in the venoms of four major families of 
venomous snakes (i.e. Crotalidae, Elapidae, Hydrophiidae and Viperidae). Some of the most 
well characterised β-neurotoxins have been identified in Australian snake venoms, including 
notexin (isolated from Notechis scutatus) the principle neurotoxic and myotoxic phospholipase 
A2 (PLA2) in Elapids (Cull-Candy et al. 1976; Hodgson and Wickramaratna 2006). These 
PLA2 bind selectively and irreversibly to specific sites with the membrane of the nerve ending 
and block neurotransmitter Acetycholine (ACh) release (Heller et al. 2007). Thus, they 
interfere with the formation of synaptic vesicles by arresting vesicle membrane recycling 
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(Fig.III). When the stores of neurotransmitter vesicles are depleted, a neuromuscular block 
results, leading to paralysis (Cull-Candy et al. 1976). Other less potent pre-synaptic neurotoxic 
PLA2 enzymes such as scutatoxin and notechis II-5 are also found in tiger snake venom (Fry 
1999).  
 
Post-synaptic action (α-neurotoxins)  
The alpha neurotoxins found in Australian Elapids are reversible postsynaptic blocking 
neurotoxins. These toxins are present in small amounts and act in a similar way: they bind with 
high affinity to skeletal nicotinic acetylcholine receptors (Fig.III) and thus prevent the binding 
between ACh and its receptors (Fry 1999). Tiger snake antivenom counteracted the 
postsynaptic, but not the presynaptic effects of tiger snake venom when they had developed 
(Fig. III) (Datyner and Gage 1973). 
 	  
Figure III. Site of action of presynaptic and postsynaptic snake venom neurotoxins (Van 
den Enden MD, Erwin. 2015).  
 Presynaptic (β-neurotoxin) and post synaptic (α-neurotoxin) toxins are represented with 
a green cross. Antivenoms are able to counteract the post synaptic action. These mecanisms 
are the main one involved in Elapids snake. 
 
Metabolic changes 
Alvarez et al. investigated the effects of several snake venoms on the Ca2+-dependent K+ 
channels of human red cells. Venom of the snake Notechis scutatus is able to irreversibly 
inhibit Ca2+ dependant K+ transport. Thus, the neuromuscular block is further potentiated by 
venom-induced metabolic changes that interfere with ions (Alvarez and García-Sancho 1989).   
	   25	  
1.1.2.2 Venom components acting on the hemostatic system 
 
1.1.2.2.1 Venom proteins acting on blood coagulation factors 
Haemorrhaging and incoagulable blood are common findings in Australian Elapids 
snakebites. Many species have the prothrombin activating enzymes in their venoms and the 
vast majority contains phospholipaseA2s (PLA2s). Elapids can be divided into two main 
classes: species with procoagagulant venom including Notechis scutatus (tiger snake) and 
species with no procoagulant venom (Fry 1999). 
 
Venom proteins acting as coagulant factors   
Venom proteins include metalloproteinases such as factors FV activators, FX activators, 
thrombin-like enzymes and prothrombin activators. Metalloproteinases affect coagulation by 
activating coagulation factors in the cascade of hemostasis (Fig.IV).  
 
Prothrombin activators are snake proteins known in Notechis scutatus and many other 
species, in the form of factor Xa-like which function is to catalyse the formation of thrombin, 
resulting in a disturbance of the coagulation cascade (Heller et al. 2007). Prothrombin 
activators are able to convert prothrombin into meizothrombin or thrombin (Birrell et al. 2007). 
According to (Rosing and Tans 1992), based on their structure, venoms can be divided into 
four groups depending on what prothrombin can be converted and depending on the cofactors 
needed. Venoms from Australian Elapids fall into either group II or group III (serine 
proteinases), able to convert prothrombin to thrombin. More precisely, tiger snake belonged to 
group II, in which activators are Ca2+ dependant and their activity increased by the presence of 
Ca
2+
, factor Va, and phospholipid (Fry 1999). Then, thrombin act as a positive feedback in the 
coagulation cascade, leading to the activation of other coagulation factors, subsequent fibrin 
formation and almost complete consumption of Factor V, Factor VIII, Factor XII and 
fibrinogen (G. K. Isbister et al. 2010). The latter consumption of coagulation factors results in 
the situation of venom-induced consumptive coagulopathy (VICC) that will be discussed 
further.  
FV and FX activators have been isolated from Viperidae, Colubridae and a few snakes 
from Elapid family, and act as procoagulant in the coagulation cascade (Lu, Clemetson, and 
Clemetson 2005). Thrombin like enzymes, mainly found in Colubridae and Viperidae, do not 
activate the same coagulation factor than thrombin (which activates FXIII). Thus, the fibrin 
formed is easily removed from the circulation and thus can act as a defibrinogenating agent 
(Fig. IV) (Tans and Rosing 2001; Lu, Clemetson, and Clemetson 2005).  
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Figure IV. Site of action of venom proteins on the cascade of haemostasis (Lu, 
Clemetson, Clemetson 2005, p1792). 
Venom proteins are surrouned in red, straight  arrows represent the activation of factor. 
Straight arrow = activation, curved arrow = conversion.  
: Inhibiton                           : Venom component             
PLA2= Phospholipase A2; IX, X BP= IX, X binding protein, tPA= tissue type Plasminogene 
activators; uPA= Urokinase plasminogene activators 
 
 
Venom proteins acting as anticoagulant factors 
While procoagulant effects are widely described, some venom proteins inhibit FIX and 
FX and thus act as anticoagulant (Morita 2004). Furthermore, Protein C activators are 
anticoagulant purified from some venoms, which degrade FVa and FVIIIa (Fig.IV) (Lu, 
Clemetson, and Clemetson 2005). Thrombin inhibitors have been found in Bothrops venom 
(Viperidae family). It has several roles including prolonged fibrinogen-clotting time by 
inhibiting competitively the binding of thrombin to fibrinogen (Zingali et al. 1993). PLA2s can 
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also be classified as strong anticoagulant due to inhibiton of FX and inhibition of the 
prothrombinase complexe (FVa, FXa, phospholipids and calcium ions) but it is not reported in 
tiger snake venom (Francis S. Markland 1998). 
 
Venom proteins acting on fibrinolysis 
Fibrinolytic and fibrinogenolytic activity has been described in the venoms of members 
of the Crotalidae, Viperidae and Elapidae families. They act by lysing fibrinogen in FPD 
(fibrinogen product degradation). Plasminogen activators (Fig.IV) act by activating 
plasminogen to plasmin, which can transform fibrin clot into FPD (F. S. Markland 1998; Lu, 
Clemetson, and Clemetson 2005). 
 
 
1.1.2.2.2 Venom proteins acting on vessel walls 	  
Many metalloproteinases described in Crotalidae, Viperidae and Elapidae venoms are 
haemorragic toxins that act in synergy to degrade the blood vessel extracellular matrix, and to 
play key roles in the development of such symptoms as haemorrhage, edema, hypotension, 
hypovolemia, inflammation, and necrosis (Hite et al. 1994; Birrell et al. 2007). 
C-type lectins belong to the composition of some Elapidae venoms and can cause 
oedema, increased vascular permeability and agglutinate erythrocytes although mechanisms 
remain unclear (Lu, Clemetson, and Clemetson 2005; Birrell et al. 2007).  
 
1.1.2.2.3 Venom proteins acting on platelets 	  
Snake venoms contain proteins acting on platelets such as PLA2s, C-type lectins, 
disintegrins and metalloproteinases binding to collagen or collagen receptors on platelets. 
PLA2s affect platelets function by several mechanisms (for example: cleaving platelet 
membrane phospholipids). Tough in many cases PLA2s induce platelet aggregations initially, 
in high concentration they will often inhibit it (Hutton and Warrell 1993). 
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Table	   III. Summary of principal types of toxin effects on the haemostatic system (modified 
from Francis S. Markland 1998). 
Toxin type Effect 
Procoagulants Prothrombin activators 
FV activators 
FX activators 
Thrombin like enzymes 
Anticoagulants Protein C activators 
Factor IX, X inhibitors 
Thrombin inhibitors 
Fibrinolytic Fibrinolytic enzymes 
Plasminogen activators 
Vessel walls interactive Haemorragin toxins 
C-type lectins 
Platelets aggregating 
agents 
PLA2s 
C-type lectins 
Desintegrins 
Metalloproteinases 
Platelets aggregation 
inhibitors 
PLA2s 
 
Examples of different venom toxins acting as procoagulant, anticoagulant, fibrinolytic 
agent, acting on vessel walls and on platelets. For example, FV activators have been described 
in Naja naja oxiana and Naja nigricollis nigricollis venoms, prothrombin activators in 
Pseudonaja textilis.  
 
1.1.2.3 Lipases 	  
The vast majority of lipases found in Australian snake venoms are phospholipases. There 
are four main species of phospholipases (A1, A2, C, D). Most venom phospholipases are 
Phosphatidylcholine 2 - Acylhydrolase (PLA2): they are the most frequently encountered 
proteins identified across the species (Fry 1999; Birrell et al. 2007). The PLA2s found in Elapid 
venom may be classified into five types: neurotoxic, haemotoxic, myotoxic, non-toxic 
enzymatically active and non-toxic non-enzymatically active (Heller et al. 2007). 
Neurotoxic PLA2s produce neurological effects not through the enzymatic esterase 
activity but rather through direct blockage (presynaptic acethylcholine release blocker) (see 
part 1.1.2.1). Notexin is the principle neurotoxic and myonecrotic phospholipase A2 in 
Notechis species (Fry 1999). 
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Haemotoxic PLA2s produce haemorrhage through blockage of factors in the coagulation 
cascade. It doesn’t produce net anticoagulation through fibrinolysis but rather bind to specific 
factors essential in the coagulation cascade (see previous part 1.1.2.2). Hemotoxic PLA2s 
isolated from the tiger snake are responsible for hypotension and haemorrhage (Fry 1999). 
Myotoxins, defined as venom components acting on skeletal muscle, act by causing 
damage to the integrity of the sarcolemma, resulting in local haemorrhage and necrosis to 
systemic skeletal rhabdomyolysis producing severe myoglobinuria (Heller et al. 2007; Mebs, 
Ehrenfeld, and Samejima 1983). The degeneration of muscle induced by the inoculation of 
either venom or pure myotoxins is rapid and followed by regeneration of the affected tissue 
(Harris et al. 2003; Heller et al. 2007). This myotoxin PLA2s has been well described in a 
particular species of Elapidae (Pseudechis australis), which differs from the other species with 
the primary toxins being myotoxic rather than neurotoxic (Fry 1999). 
Non-toxic PLA2s have also been isolated from the tiger snake and do not present any 
toxic activity (Fry 1999).  
Moreover, PLA2s are known to play a role in the hyperalgesia induced by Bothrops asper 
venom (Chacur et al. 2001) and may play a role in the inflammatory process ( Fry 1999; Cher 
et al. 2003), which will be further detailed (see part 1.2.3.2).  
Other lipases such as lyophospholipases and phospholipases also exist and are 
responsible for haemolysis and myolysis (Heller et al. 2007). 
 
1.1.2.4  Venom component specific to Elapid snakes 	  	  
The venom protein components of 18 Elapid snake species were separated and identified 
using mass spectrometry and peptide sequencing. Three groups of proteins account for a large 
proportion of the total venom proteins, confirming their high abundance: neurotoxins, 
prothrombin activators, and PLA2s (Tabl. IV).  
 SVMPs, known in Viperidae venoms has been identified in 7 out of the 18 Elapid 
species (species non precised). A limited number of C-type lectins have also been identified in 
this study in some Elapids.  
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Table IV. Venom protein components of Elapid snake species and their main effects on the 
organism (modified from Birrell et al. 2007) 	  
Toxin type Effect 
Neurotoxins 
Neurological signs (mydriasis, 
paralysis, etc.) 
Prothrombin activators Consumptive coagulopathy  
Phospholipases A2 
Neurological signs, muscle 
degeneration, necrosis, 
inflammation 
SVMP 
Hemorrhage, oedema, 
hypotension, hypovolemia, 
inflammation, and necrosis 
C-type lectins Oedema, increased vascular permeability 
 
Neurotoxins, prothrombin activators and phospholipases A2 (highlighted) represent the 
three major groups of components found in tiger snake venom.  
 
 
1.1.3 CLINICAL PRESENTATION OF SNAKE ENVENOMATION IN DOGS  
 
 
Clinical effects of snake envenomation include local, general, neurological, 
haematological and myotoxicity signs (Tabl.V). 
 
Clinical effects at the bite site 
At the bite site, the envenomation can cause locally painful and redness, swelling, and 
bruising. It is usually local minor effects although necrosis may occur. Fang puncture or scratch 
marks can be visible and helpful for the diagnosis (Geoffrey K. Isbister et al. 2013). A study on 
53 dogs envenomed by Vipera berus showed a varying degree of swelling in the area of the 
bite. The bite site was located in the head/nose in 77% of dogs, in the hind limb in 13%, the 
front limb in 6%, the neck and prepuce in 2% each (Lervik, Lilliehöök, and Frendin 2010). 
Nevertheless, in Elapids envenomation, snakebite is not always visualized, as in other studies 
of tiger snake bites in which wounds were seen in only 9 on 125 dogs (Barr 1984) and 1 on 104 
dogs (Indrawirawan et al. 2014) and were generally found on the face. It can be due to the 
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difficulty of identification of the wound (and the fact that the face has less hair than other parts 
of the body) as well as a lower sever local response.  
 
General signs  
Non-specific signs such as ptyalism (10%), vomiting (38% to 42% according to the 
authors) and generalised muscle weakness/collapse (around 30%) or reduced level of 
consciousness (14%) are common signs in tiger snake envenomation on dogs (Barr 1984, 
Indrawirawan et al. 2014). Collapse is usually described but often followed by rapid recovery 
(29%, Indrawirawan et al. 2014). Tachycardia, tachypnea or dyspnea are usually found in tiger 
snake envenomation, controversially elevated rectal temperature is not usual. Draining lymph 
nodes may also be tender (Barr 1984). These findings are also observed in humans envenomed 
by tiger snake (Geoffrey K. Isbister, Brown, and ASP Investigators 2012). 
 
 
Neurological signs  
Neurologic signs are also a common finding on dogs following a snake envenomation, 
including by tiger snake. Experiments on mice have shown the relationship between the dose 
and the severity of the disease, suggesting that these signs depend on the amount of venom 
injected at the bite site (Lewis 1994).  
The earliest signs are usually disorientation and ptosis, which develops from one to 
several hours after the bite. Mydriasis and loss of pupillary light reflex, which is consistent with 
a paralysis of oculomotor nerve, are common findings and more particularly the most 
commonly observed signs in a study on tiger snake envenomation (76% and 66% of dogs 
respectively) (Barr 1984). In a more recent study on 21 dogs envenomed by tiger snake, 
mydriasis was observed on 29% of the dogs and reduced pupillary reflex on 24%. These 
numbers can be underestimate since they only include tiger snake envenomation confirmed by 
SVDK, professional snake handler or scale counting and do not include “suspected tiger snake 
envenomation” (Indrawirawan et al. 2014). In a study on 53 dogs, 73% of them had an affected 
mental status on arrival at the hospital, but this study was concerning only Viper envenomation 
(Lervik, Lilliehöök, and Frendin 2010). Then paralysis of facial, peripheral and 
glossopharyngeal muscles may occur and thus conduct to respiratory failure. Generalized 
paralysis is an important feature of tiger snakebites, but clinical evidences of flaccid paralysis 
take several hours to become apparent.  
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 These neurological effects are usually reversed with antivenom if given prior to 
development of major paralysis. If many hours after the bite, the patient presents a major 
paralysis requiring intubation and ventilation, it may be necessary to continue this treatment for 
days, weeks, and very occasionally, even over a month (Fry 1999; Hodgson et al. 2003; 
Geoffrey K. Isbister et al. 2012).  
 
Haematological signs 
Coagulopathies are well known in snake envenomation and may result in clinical signs 
such as increased bleeding (linked to decreased blood coagulability or to endothelial damages), 
hypovolemic shock and secondary organ damage, macro- and microthrombosis, such as 
pulmonary thromboembolism (Goddard et al. 2011). Australian Elapids venom toxins act as 
procoagulants, causing in-vivo activation of the coagulation system, but in most cases, this does 
not result in massive thrombosis and consequent embolic disease, but rather causes 
consumption of coagulation factors, resulting in clinical anticoagulation. It may cause 
important abnormalities of clinical laboratory tests, but generally does not result in clinically 
significant bleeding (White 2005). 
Bleeding from bite site or venupuncture site (hematoma, ecchymosis), oral and nasal 
cavity (epistaxis, petechial haemorrhages), gastrointestinal (melena), urinary and intracranial 
sites, may occur (study non specific to tiger snake) (Geoffrey K. Isbister et al. 2013). 
Discolouration of the urine is a common finding, reported in 25% of the dogs envenomed by 
tiger snake (Barr 1984) but can be the result of haemoglobin, myoglobin or erythrocyte’s 
presence.  
 
Myotoxicity signs 
Severe myolysis can occur with tiger snakebites, particularly if treatment is delayed or 
inadequate. Myotoxicity was seen in 59% of the dogs envenomed by tiger snake (Indrawirawan 
et al. 2014) and is generally characterized by increased Creatine Kinase (CK). The usual signs 
may occur, e.g. muscle tenderness, muscle weakness, pain on contracting muscles, 
myoglobinuria and later development of muscle wasting (Geoffrey K. Isbister et al. 2012). 
   
Renal failure 
No renal toxins have so far been isolated from tiger snake venoms, but renal failure is a 
common effect of tiger snakebites in humans, for cases with significant envenoming.  
Nevertheless it is not usual in dogs, in which only a few isolated cases are reported (Warrell 
2010). 
	   33	  
Histopathology findings  
A study has described the examination of post mortem heart, lungs, kidneys and 
gastrocnemius muscle tissue from one dog envenomed by a tiger snake. Pathological evidence 
of procoagulant venom activity with formed thrombi has been observed in the lungs, heart, 
muscles and kidneys. This supports the proposal that an initial thrombotic state occurs in 
envenomed dogs, leading to the depletion of vital clotting factors and thus to coagulopathy. 
Nevertheles, it is unclear whether renal failure is a direct result of the venom’s nephrotoxicity 
or a secondary effect of myoglobinuria (Jacoby-Alner et al. 2011). 
 
Table V. Clinical presentation of snake envenomation 	  
Clinical signs Presentation 
Local signs Not usualy visualized. Pain, red, swelling and bruising Scratch marks 
General signs 
Ptyalism, vomiting 
Collapse / Reduced level of consciousness 
Weakness 
Tachycardia, tachypnea, dyspnea 
Tender lymph nodes 
Neurological 
signs 
Disorientation 
Ptosis, mydriasis, loss of pupillary light reflex 
Ataxia, generalized weakness, paralysis 
Haematological 
signs 
Mostly laboratory findings (bleeding, hypovolomic shock not frequent) 
Discoloration of urines 
Myotoxicity signs Muscle tenderness, weakness, pain 
 
Clinical signs associated with snake envenomation include local, general, neurological, 
haematological and myotoxicity signs. The most frequently observed clinical signs in tiger 
snake envenomation on dogs are highlighted. 
. 
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1.1.4 CLINICOPATHOLOGICAL VARIABLES ASSOCIATED WITH 
OPHIDIAN ENVENOMATION 	  
1.1.4.1 Biochemistry  	  
 
Many biochemical abnormalities have been described in snake envenomation (Tabl. VI) 
and may help the veterinarian to detect pathologic effects. Myotoxicity is the most affected 
biochemistry parameter described on tiger snake envenomation in the literature. Other 
biochemical abnormalities are described in various snake species. 
 
Muscle activity: myotoxicity 
In humans, CK (Creatine Kinase) activity is an indicator of many factors (like the amount 
of venom injected, the delay between envenomation to presentation and the quantification of 
myonecrosis) (Nakada et al. 1984) but its use is limited in dogs since it is often difficult to 
know the exact time of snakebite (Goddard et al. 2011). In an in-vivo study on mice, from six 
Australian Elapid venoms, only those from Pseudechis colletti guttatus and Pseudechis 
australis produced a rise of CK-activity. They also showed that a fraction of the Elapid snake 
Pseudechis colletti guttatus venom, the Phospholipase A2, caused a dose-dependent increase of 
CK-level and myoglobinuria (Mebs, Ehrenfeld, and Samejima 1983). Elevated CK were found 
in most cases of several studies: 15 out of the 28 sampled dogs (54%) 24h after admission on 
Viperidae envenomation (Lervik, Lilliehöök, and Frendin 2010), 75 out of 109 dogs (69%) in 
another study on Viperidae envenomation (Aroch and Harrus 1999) and 43 out of  the 45 dogs 
(96%) on tiger snake envenomation (Barr 1984). In a more recent study on tiger snake 
envenomation, myotoxicity was seen in 59% of dogs with tiger envenomation, with a median 
CK activity of 1,878 U/L; the highest CK value was 62,586 U/L (Indrawirawan et al. 2014). In 
some of these studies, it was suggested that CK values were within the reference values, mainly 
for samples that were collected too early after snakebite (before the release of plasma CK from 
degenerating muscle) or too late in the envenomation process (after excretion by the kidneys). 
The increased CK activity may be related to rhabdomyolysis induced by snake venom 
myotoxicity and also to intravascular hemolysis. 
 
Hepatic variables: hepatotoxicity 
Hepatic variables changes associated with snake envenomation have mostly been 
described in Viperidae family. In a study on 34 dogs envenomed by Vipera berus, 65% had a 
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serum concentration above reference values for at least one liver enzyme  (Alanine Amino 
Transferase ALT, Alkaline Phosphatase ALP, Lactate Deshydrogenase GLDH and bile acids) 
during one or more examinations (on arrival, at 24h, at follow-up on the period of days 4-10 
and days 9-23). But in most cases, the increase was mild, temporary and only one or two 
parameters were affected (Lervik, Lilliehöök, and Frendin 2010). High increased of these 
variables have also been described in dogs envenomed by Vipera palaestinae. These findings 
have suggested hepatocellular damages and cholestasis, as a consequence of vascular ischemia 
as well as direct damages by cytotoxin effects of snake venom. An increase to some degree in 
ALAT and ASAT may also be explained by muscle damages and by glucocorticoid treatments 
(Aroch and Harrus 1999, Goddard et al. 2011). 
 
Renal variables: nephrotoxicity 
According to Lervik, Lilliehöök, and Frendin (2010) and Segev et al. (2008), the serum 
creatinine was within the reference values for all dogs at all examinations. Nevertheless some 
cases of acute renal failure have been described in dogs’ envenomation. For example, a dog 
bitten by en Elapid snake, the Red-bellied Black snake (Pseudechis porphyriacus), with signs 
of rhabdomyolisis and hemolysis (increased CK, bilirubine and ASAT) presented moderate 
increased creatinine, azotaemia and marked hyperphosphataemia consistent with renal failure. 
This dog presented evidence of shock, dehydration, with discoloured and reduced urine 
production and became totally anuric before euthanasia (Heller et al. 2006). Renal failure may 
be due to renal ischemia caused by vasoconstriction and procoagulant microthrombotic effect, 
nephrotoxic effects of myoglobinuria, hemoglobinuria, DIC (disseminated intravascular 
coagulopathy), toxic nephropathy, and hypovolemic shock (Goddard et al. 2011, Heller et al. 
2007). 
 
Other biochemical abnormalities: 
Other abnormalities have been especially shown in dogs envenomed by Vipera 
palaestinae e.g.: hyperalbuminemia, hyperglycemia, hypocholesterolaemia, hypoalbuminemia 
and hyperproteinemia (Aroch and Harrus 1999; Segev et al. 2004; Segev et al. 2008). Moderate 
hyperalbuminemia could be the consequence of hemolysis and/or ischemic hepatopathy 
(Goddard et al. 2011). Hyperglycemia can be linked to stress and pain (Segev et al. 2004). 
Hypocholesterolaemia and hypoalbuminemia may be explained by capillary damages and 
changes in lipoprotein transport and metabolism due to the phospholipase A2 (Segev et al. 
2004). Total cholesterol level was also assumed to be inversely correlated to the severity of the 
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envenomation in human cases (Winkler et al. 1993). These abnormalities are poorly described 
on tiger snake envenomation. 
 
1.1.4.2 Heamatology markers 	  
1.1.4.2.1 RBC abnormalities 
 
Hemoconcentration, characterized by an increased in hematocrit and hemoglobin 
concentration is a common finding on envenomation by puff-adders from Viperidae family and 
cobras from Elapidae family (Segev et al. 2004; Segev et al. 2008; Lobetti and Joubert 2004; 
Aroch et al. 2010). This abnormality can be explained by fluid losses, associated with third 
spaces due to heamorrhagins inducing capillary damages and the shift of proteins and fluids 
from circulation to the inflamed tissue at the bite site. Splenic contraction may also be involved 
associated with excitement, pain, and stress and subsequent release of stored erythrocytes into 
circulation. Dehydration was eliminated as a prominent cause of increased hematocrit based on 
lack of clinical evidence (Lobetti and Joubert 2004; Goddard et al. 2011). 
Haemolysis is well described in snake envenomation, especially in the Elapid red-bellied 
Black Snake. First evidence is a discolouration of serum (Heller et al. 2006). Another evidence 
is red urine, although it could be the result of bleeding, hemoglobinuria or myoglobinuria and 
thus imply hemolysis, rhabdomyolysis, or renal damages (Heller et al. 2006). Nevertheless, in 
an in-vivo study on experimental administration of tiger snake venoms in dogs, although 
haemolysis appears quickly with plasma haemolized in 30 mintes and even at low doses of 
venom injected, it didn’t seem to progress significantly. Haemolysis is thought to be the 
consequence of lytic factor or phospholipase activity which damages the erythrocyte cell 
membrane and results in an influx of water, leading to erythrocyte swelling, stretching and, 
ultimately, haemolysis (Goddard et al. 2011; Heller et al. 2006). The haemolysis is sometimes 
accompanied by echinocytosis and spherocytosis (Aroch and Harrus 1999). 
Anemia has been observed less frequently in dogs with snake envenomation (Goddard et 
al. 2011).  	  
1.1.4.2.2 Leukocytes abnormalities 	  
Leukocytosis also characterizes envenomation in dogs, suggesting an acute inflammatory 
reaction. It has been described on envenomation by Viperidae such as the puff adders (Bitis 
arietans) and the palestine viper (Vipera palestinae) and by cobras from the Elapidae family 
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(Lobetti and Joubert 2004; Aroch and Harrus 1999; Goddard et al. 2011; Segev et al. 2004). 
Leukocytosis was identified as a risk factor for mortality in dogs with Vipera palaestinae 
envenomations (Aroch and Harrus 1999; Goddard et al. 2011). 	  
1.1.4.3 Hemostatic changes 	  
1.1.4.3.1 Platelets abnormalities 	  
Various degrees of thrombocytopenia are commonly found: for example, on dogs 
envenomed by Vipera palestinae, 51.9% have shown thrombocytopenia at the venom 
admission and 52% 24h post admission (Aroch and Harrus 1999). A fall in the platelet count is 
usually evident within 24 hours of the bite (Geoffrey K. Isbister 2010).  In a mouse model, 
platelet numbers were significantly decreased 30 minutes after Bothrops asper snake venom 
injection and returned to normal after 12 hours (Lomonte, Tarkowski, and Hanson 1993). 
Several mechanisms could explain thrombocytopenia in envenomation such as vasculitis, 
sequestration of platelets in inflamed tissues, and consumption of platelets with potential 
development of disseminated intravascular (Goddard et al. 2011). It is poorly described in tiger 
snake envenomation. 
Interaction of snake venom with platelets aggregation are reported. Some PLA2s seem to 
induce platelet aggregation by cleaving platelet membrane phospholipids, releasing arachidonic 
acid and forming arachidonic acid metabolites such as thromboxane A2. Another group of 
PLA2s inhibit platelet aggregation via the cleavage products (Lu, Clemetson, and Clemetson 
2005). 
 
1.1.4.3.2 Vascular abnormalities: coagulopathy 	  
As seen earlier (part 1.1.2.2.), a large number of venom proteins act as procoagulants, 
sometimes as anticoagulants, that then create thrombosis, consumption of coagulant factors and 
thus may result in incoagulable blood and bleeding (Fry 1999; White 2005). Coagulopathy is a 
common finding in snake envenomation and Australian Elapids are amongst the most potent in 
causing procoagulant coagulopathy (White 2005).  
 
Coagulation testing in envenomed dogs is mainly characterized by coagulopathy 
evidence such as increased Prothrombine Time (PT) and activated Partial Thromboplastin Time 
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(aPTT), decreased fibrinogen, increased Fibrin/ fibrinogen degradation products (FDP) or D-
Dimer levels, hypoantithrombinemia activity. An observation on blood coagulation in cats and 
dogs naturally envenomed by tiger snake showed that all dogs (n=6) had an increased PT and 
an increased aPTT, and half of them (n=3) had increased FDP levels (Holloway and Parry 
1989). Later, other studies showed similar results in Viper envenomation with prolonged PT 
and aPTT at admission (68.4% and 21.1% of the dogs respectively (Segev et al. 2004), 29% 
and 39% of the dogs in (Aroch et al. 2010)) and further prolonged aPTT a day later (75.8%  of 
the dogs). Prolonged PT and aPTT were observed in 54% and 44% of the dogs respectively, at 
least once during the experiment. Hypoantithrombinemia was observed at least once in 56% of 
the cases and D-dimer concentrations were positive (>250 ng/mL) in 90% (Aroch et al. 2010). 
In these studies, the authors recommended that dynamic multiple coagulation tests should be 
realized as the incidence of abnormalities was associated with higher mortality. 
Thromboelastography may also be an helpful diagnosis of coagulopathy (Goddard et al. 2011). 
 
Presence of thrombocytopenia, increased PT and aPTT may lead to the diagnosis of DIC 
(Disseminated Intravascular Coagulopathy). Nevertheless, in Elapid envenomation, and 
especially with tiger snake species, this consumptive coagulopathy associated with snakebites 
has been referred to as a VICC, Venom Induced Consumption Coagulopathy (Goddard et al. 
2011). VICC is characterized by prolonged clotting times, depletion of fibrinogen and cofactors 
V and VIII, and high concentrations of FDPs. However, it does not include evidence of 
thrombus formation and organ failure. In a study on tiger snake envenomation on dogs, 
laboratory evidence of a coagulopathy was detected in 12 out of 21 dogs (57%) envenomed by 
confirmed tiger snake and in 34 out of 41 dogs (83%) with suspected tiger snake envenomation 
(Indrawirawan et al. 2014). These numbers are lower than those observed in human literature 
where VICC was observed in 95% of tiger snake victims (Geoffrey K. Isbister et al. 2012). It 
was suggested that dogs are less sensitive to the procoagulant effects of tiger snake venom than 
humans (Indrawirawan et al. 2014). 	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Table VI. Laboratory evidences of snake envenomation 
Laboratory 
evidence 
Affected parameters  
Myotoxicity High CK levels 
Hepatotoxicity High ALP, ALT, GLDH, bile acids levels 
Nephrotoxicity High Creatinine levels 
RBC 
abnormalities 
Haemoconcentration (increased Ht) 
Haemolysis (haemolized plasma, red urines) 
Anemia  
Leukocytes 
abnormalities 
Leukocytosis 
Platelet 
abnormalities 
Thrombocytopenia 
Coagulopathy Increased PT, aPTT 
Raised D-Dimer concentration 
Low to undetectable fibrinogen (VICC) 
 
Laboratory evidences highlighted represent those mostly altered in tiger snake 
envenomation.  
CK = Creatine Kinase, ALT = Alanine Amino Transferase, ALPalkaline phosphatase ALP, 
lactate deshydrogenase GLDH, PT = Prothrombin Time, aPTT = Activated Partial 
Thromboplastin Time, VICC= Venom Induced Consumption Coagulopathy.  
 
 
1.1.5 DIAGNOSIS OF SNAKE BITES 
 
The diagnosis of snake envenomation is lead by the association of several factors 
(Diag.2). First of all, the presence of envenomation should be done on arrival with the history, 
clinical evidence and laboratory test. If none of the clinical or laboratory evidence can be 
observed, further exams should be run some hours later with a neurological examination in 
order to exclude snakebite. If envenomation has been identified, then the vet should determine 
which snake or group of snakes is most likely to be involved - with use of pictures, scale 
counting, geographic prevalence and SVDK (Snake Venom Detection Kit).  
 
If the diagnosis is established, appropriate antivenom that covers the likely snake(s) is 
given. Nevertheless, in veterinary medicine, due to financial reason or to a long elapse time 
between the bite and the animal presentation, antivenom is sometimes used directly after the 
history and examination. Then, the diagnosis would be based on clinical improvements 
following the antivenom administration (Geoffrey K. Isbister et al. 2013). 
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Diagram 2.  Key steps for snakebite diagnosis  
Two main steps are important to consider: diagnosis of snake envenomation and 
determination of the snake immunotype.  
 
1.1.5.1 History 
 
History is essential to make a diagnosis of snakebite. A detailed history of the 
circumstances of the bite (time, temperature, geographic location), of the witnessed snake 
(length, colouring, use of scale counting), of the first symptoms (vomiting, period of 
unconsciousness, collapse, etc.) and medical history as well should be taken into account, 
according to human’s guide but applicable in domestic animals  (White, 2013). 
Nevertheless, as seen previously (see part 1.1.1), the identification of the snake by non-
professional people, without any pictures taken or scale counting, is not reliable in the majority 
of cases.  
 
1.1.5.2 Clinical evidence  
 
Clinical evidence includes the clinical presentation (neurological, haematological and 
myotoxicity signs) presented previously (see part 1.1.3, Tabl. V). Fang marks at the bite site 
can be reliable clue of snakebite but is not always observed. 
 
1.1.5.3 Laboratory tests 	  
It is necessary to use clinical signs in conjunction with the history, the physical 
examination, the laboratory investigation and the venom detection kit. Iterative laboratory 
Snake bite diagnosis: 
Key steps 
History 
Examination 
Laboratory tests 
Determining the  
snake immunotype 
Identifying the snake 
species (photo, scale 
counting) 
Geographic location 
SVDK 
Use of antivenom and 
clinical improvement 
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testings and neurological assessments are recommended on admission, 6 hours and 12 hours 
after the bite (Ireland et al. 2010). 
 Like in human management, an initial full set of investigations should be made on dogs 
with a suspected snakebite. Nevertheless, some investigations traditionally done are not always 
available or cannot be conducted for financial reasons. In humans, it has been shown that the 
most appropriate combination of tests to reliably detect envenomed patients within 12 hours 
was INR (International Normalized Rates), aPTT and CK level associated with neurological 
examinations (Ireland et al. 2010). 
 
1.1.5.4 Snake venom detection kit (SVDK) 
 
Description 
SVDK is a rapid sandwich enzyme immunoassay, used in order to detect the immunotype 
among the five major snakes in Australia (tiger, brown, black, death adder and taipan). The test 
gives a visual and qualitative result within 15 to 25 minutes and can detect as little as 
0.01ng/mL of snake venom in a sample. Therefore, it is not an indication to give antivenom but 
its primary use is to assist veterinarians in choosing the most efficient antivenom therapy 
(Manufacturer data). 
Principle         
 Antibodies against a particular immunotypes of the five snakes overrepresented in 
Australia are present in each well of the kit.  First, the test sample is diluted in Yellow Sample 
Diluent, added to the test wells and incubated for 10 minutes at the room temperature. Any 
venom present in the test sample binds to the antibodies in the well and then, wells are washed 
to remove any unbound venom and conjugate. To finish, chromogen and peroxide solution are 
added to each well, resulting in the development of a blue color considered positive for a 
specific venom immunotype (Manufacturer data). 
Sample selection 
Test specimen options include bite site swab, affected clothing or bandage, urine, plasma 
or serum, heparinised whole blood (other anticoagulants may also be used), other tissue and 
biological fluids. Generally bite sites are harder to locate in veterinary cases and thus, urine or 
whole blood is commonly used. The best samples for venom detection are bite site swab 
(Manufacturer data; Heller et al. 2007). 
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Test Interpretation  
 If wells 1 to 5 show no colour change, no venom has been detected from the five most 
clinically important venom immunotypes. Tiger immunotype is detected if well 1 changes to 
blue first. In this case, the SVDK may have detected Tiger, Copperhead or Rough Scaled Snake 
venom (Fig.V). Clinical envenomation from these snakes should be treated with CSL tiger 
snake antivenom. 
   
Figure V. Snake venom detection kit: correspondence of wells and snakes immunotypes 
and antivenom indicated (SVDK, manufacturer data) 	  
Sensibility and specificity 
The manufacturer has not published any information on the diagnostic sensitivity and 
specificity of this kit for snake envenomation.  
In the veterinary population, the specificity of the test in urines samples is reported in 
only one study. There was no false positive in this study, suggesting a specificity of 100% 
(Ong, Swindells, and Mansfield 2010). Nevertheless, cross-reactivity to venoms from non 
venomous and mild venomous snakes have been shown in humans literature (Jelinek et al. 
2004). These cross-reactions were also observed with other venomous Elapids, although they 
were found to be low and, remarkably, most apparent between greatly divergent venoms 
(Steuten et al. 2007). Moreover, in human literature, the SVDK has shown high rates of 
inaccuracy with a high level of false positives, false negatives and problems of cross-
reactivities. This includes misdiagnosis of brown snake envenomation in one of the 10 cases of 
tiger snake envonomation in humans literature (Geoffrey K. Isbister et al. 2012), an incorrect 
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result in 14% of snakes where an expert identification was available and false negatives when 
no venom is detected in around 25% of envenomed patients (Geoffrey K. Isbister et al. 2012). 
Let’s note that SVDK may not be of practical use if the severity of the case doesn’t allow 
waiting for a result.  
 
1.1.6  TREATMENT 
 
1.1.6.1 First aid treatment 
 
In human literature, first aid treatment includes immobilizing the patient in order to slow 
the systemic spread of the venom from the bitten area and thus delay the envenomation 
syndrome. Indeed, tiger snake venom is known to be distributed systemically within the 
lymphatic system and thus, the application of a firm crepe bandage with immobilization by a 
splint can effectively delay venom distribution through the body and can be also efficient on 
dogs. Pressure alone or immobilization alone did not delay venom movement (Sutherland, 
Coulter, and Harris 1979; Heller et al. 2007) . 
 
1.1.6.2 Antivenom treatment 
 
Production and composition 
Antivenom is formulated from the serum of horses immunised with the venom of snakes 
(hyperimmune Immunoglobulins G, IgG, serum) (CSL, 2014). Antivenoms are obtained 
following a complex production process. After venoms collection and mixture from individual 
venomous snakes, the preparation is injected to the animals (generally horses). Once the 
immune response to the immunizing venom mixture has yielded satisfactory antibody levels, 
blood or plasma is collected from the immunized animals. Antivenoms are then prepared using 
diverse methods to obtain intact IgG molecules or secondary fragment antigen binding F(ab')2. 
Many fractionation processes exist leading to the degradation of many non-IgG proteins, and to 
the cleavage of IgG into bivalent F(ab')2 fragments by removal and digestion of the fragment 
cristallizable Fc fragment into small peptides (World Health Organization, 2010). 
 
Formulation 
Several formulations of antivenoms are available. Monovalent antivenoms are used 
against envenomation of one species of snake (Tabl. VII).  
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Bivalent antivenom allow to treat dogs envenomed by two species, and is especially used 
when no reliable identification was made and when two species are known to be easily 
confoundable or highly prevalent in a region. For example, the retrospective study conducted in 
Melbourne Hospital in Victoria noted that the manufacturers of tiger and brown snake 
antivenom recommend that both antivenoms (bilavent Tiger and Brown snake) should be 
administered in Victoria if the snake cannot be identified. Nevertheless, they think by their 
experience that monovalent tiger snake antivenom alone would cover nearly all envenomations 
from the Werribee area due to tiger snake prevalence in this area (Barr 1984). 
 
Table VII. List of monovalent antivenoms available from CSL and corresponding snake 
venoms neutralised (modified from SVDK, manufacturer data) 
Monovalent Antivenom Snake Venoms neutralised 
Tiger snake Tiger snake (Notehis scutatus), Copperhead (Austrelaps superbus) 
Red bellied black snake (Pseudechis porphyriacus) 
Rough Scaled snake (Tropidechis carinatus) 
Blue bellied snake (Pseudechis guttatus) 
Broad Headed snake (Hoplocephalus bungaroides) 
Pale Headed snake (Hoplocephalus bitorquatus) 
Stephen’s Banded snake (Hoplocephalus stephensi) 
Sea snake 
Brown snake Common or Eastearn brown snake (Pseudonaja textilis) 
Dugite (Pseudonaja affinis) 
Western brown snake (Pseudonaja nuchalis) 
Black snake Mulga snake (Pseudechis australis) 
Papuan black snake (Pseudechis papuanus) 
Red bellied black snake (Pseudechis porphyriacus) 
Blue bellied snake (Pseudechis guttatus) 
Butler’s mulga snake (Pseudechis butleri) 
Death adder Common death adder (Acanthophis antarcticus) 
Desert death adder (Acanthophis Pyrrhus) 
Northern deathnadder (Acanthophis praelongus) 
Pilbara death adder (Acanthophis sp) 
 
Taipan Taipan (Oxyuranus scutellatus) 
Inland taipan (Oxyuranus microlepidotus) 
Papuantaipan (Oxyuranus scutellatus canni) 	  
A polyvalent antivenom neutralises the venom from all of the known medically important 
venomous snakes found in Australia. However, the bigger the required volume is, the higher 
the risk of adverse reactions is. Consequently, smaller volumes of monovalent antivenoms are 
more efficient and must be used if possible (SVDK manufactura).  
 
Indication and posology 
As seen previously, administration of antivenom is indicated wherever there is evidence 
of systemic envenomation: a positive result of SVDK in the absence of clinical evidence should 
not be a reason to give a treatment.  
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Two retrospective studies compared the benefits of antivenom on dogs envenomed by 
Crotalidae. Amongst the parameters evaluated, there were not any significant benefits 
associated with antivenom administration (Katzenbach and Foy 2015; McCown et al. 2009). 
Nevertheless, an important bias is highlighted by the fact that antivenoms were probably given 
when the severity of clinics was increased.  
In human literature, Australian snake antivenom has been clearly proved to efficiently 
improve life-threatening systemic effects resulting from envenomation and especially to treat 
venom-induced coagulopathy (MacDonald, White, and Currie 2008). In Elapid envenomation, 
its use has been associated with considerable reduced or absent coagulopathy and myotoxicity 
after antivenom therapy (study on mulga snake) (Johnston et al. 2013; Heiner et al. 2013). The 
procoagulant effects have also been shown to be neutralized by the antivenom in a study on 
brown snake envenomation. In this study, the median venom concentration on blood sample of 
27 envenomed patients was 20 ng/mL prior to antivenom and was not detected after antivenom 
administration (Geoffrey K. Isbister et al. 2007). 
The posology is still a controversial issue in literature. In human medicine, the use of 
more than one vial or repeated doses of tiger snake antivenom is no longer recommended and 
the recovery of most clinical syndromes such as coagulopathy has not been found to improve 
following additional doses of antivenom (Geoffrey K. Isbister et al. 2012). Nevertheless, in the 
Australian Veterinary Journal, a review specifies that the amount of vials required depends on 
the amount of venom instilled and that tiger and brown snake species, may require substantially 
more than the recommended dosage (Heller et al. 2007).  
Tiger snake antivenom therapy is more effective if it is given as soon as possible after the 
bite and delays in antivenom’s administration may conduct to delayed response or slow 
recovery (Barr 1984). In a study on rattlesnakes (Viperidae family), antivenoms are 
recommended to be optimally given during the 4 hours following the snakebite, but they are 
still effective up to 24 hours or longer after envenomation (Juckett and Hancox 2002). 
 
Adverse reaction 
Acute adverse reactions occur on average in 5 to 7% of dogs envenomed by Viperidae or 
Crotalidae. Some clinical signs described are anaphylactic reactions, including fever, swelling 
and facial pruritus, vomiting, bradycardia, tachycardia, hypotension, and respiratory distress 
(Lund et al. 2013; McCown et al. 2009). Some other studies do not describe any adverse 
reactions (Aroch and Harrus 1999; Segev et al. 2004).  
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Delayed forms called serum sickness, have also been reported in humans from 4 days to 2 
weeks after the antivenom’s administration. There are no specific published reports of 
anaphylaxis in dogs due to Elapid snake antivenom’s administration or serum sickness. 
However both effects are documented in humans (Heller et al. 2007). 
 
1.1.6.3 Prophylactic treatment and symptomatic supportive treatment 
 
Empirical therapy should include oxygen administration, wound management, fluid 
therapy and analgesic drugs.  
 
Antimicrobial use 
Local disinfection should always be done if local manifestations are visualized. Due to 
the potential presence of microbial agent, the prophylactic use of antibiotics has been 
questioned. Antibiotic prophylaxis has been shown to be inefficient in decreasing the incidence 
of local infection. Results from several studies (Jorge et al. 2004; Ericsson et al. 2006; Lervik, 
Lilliehöök, and Frendin 2010) are in accordance, as they found no clinical signs of infection in 
any envenomed dogs despite that only 19% of dogs were treated with antibiotics. Nevertheless, 
the use of antibiotics is still largely used in veterinary clinics: 85% to 90% of dogs received 
antibiotics in two studies (Lobetti and Joubert 2004; McCown et al. 2009).  
 
Fluid therapy and blood transfusion 
The type of fluid must be chosen after assessment of the clinical signs, the acid-base 
status, the degree of hypovolaemia, and the presence of renal failure and coagulopathy. Isotonic 
crystaloid solutions (70–90 mL/kg in fractioned doses) are more recommended than colloides 
use, associated with potential decrease in platelets (Armentano and Schaer 2011). Most of the 
time, blood transfusion is not required (around 7% in (Lobetti and Joubert 2004)) but it may be 
necessary in cases of uncontrolled bleeding due to coagulopathy (Barr 1984; Heller et al. 2007). 
 
Analgesics 
Analgesics should be given depending on clinical signs associated. Either lidocaine, 
buprenorphine, fentanyl and morphine may be given at the discretion of the clinician, although 
morphine should be avoided due to the risk of histamine release and hypotension (Armentano 
and Schaer 2011). Generally, non-inflammatory drugs and opiods are given to improve animal 
comfort (Lobetti and Joubert 2004). 
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Premedicants before antivenom administration 
The use of premedicants to reduce the incidence of anaphylaxis secondary to snake 
antivenom administration is controversial within the literature. In human literature, adrenaline 
premedication appears to significantly reduce acute adverse reactions to antivenom 
administration without secondary effects (Williams et al. 2007; Premawardhena et al. 1999). 
The use of promethazine and hydrocortisone premedication observed in the same study was 
inefficient (Williams et al. 2007). Nevertheless, some side effects with the use of 
antihistaminics such as hypotension have been described and can be a non indication in 
coagulopathic patient ( Heller et al. 2007; Armentano and Schaer 2011). Moreover, as seen 
previsouly, the incidence of acute reactions following antivenom administration in dogs is 
relatively low (see part 1.1.6.2). 
 
Corticosteroids use 
The use of corticosteroids is still very controversial. Indeed, some authors think that 
steroids may slow and diminish the response to antivenom and increase the risk of infection 
(Sutton, Bates, and Campbell 2011). In another study, no clinical or clinicopathological 
parameters have been shown to be modified with the use of a single dose of prednisolone 
1mg/kg subcutaneously (Brandeker et al. 2015). Moreover, some studies have shown an 
increased mortality associated with the use of corticoids, suggesting that their use could even 
be harmful. Nevertheless, it has been highlighted that corticoids are more likely to be 
administrated if clinical signs were more pronounced which may influence on the mortality rate 
(Segev et al. 2004). Finally, inflammatory reaction induced by snake venom are commonly 
described (see part 1.2) and the use of corticosteroids may be helpful by inhibiting 
cyclooxygenases (COX) and thus preventing the release of arachidonic acid and other 
mediators of inflammation. No specific study has been conducted in tiger snake envenomation. 	  	  	  
1.1.7 PROGNOSIS 
 
Mortality rates in dogs are variable ranging from 1% to 30% (Lund et al. 2013; 
Armentano and Schaer 2011; Segev et al. 2004; Aroch and Harrus 1999).  In the study on tiger 
snake envenomation, survival rates for dogs envenomed by this species and treated at the 
hospital were 67% (Barr 1984). In another study on tiger and brown snake envenomation, the 
survival rate for dogs that received antivenom was 95% (Indrawirawan YH, 2014). 
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According to Segev et al., dogs presented with the following variables were more likely 
to die: body weight below 15kg, limb envenomation, envenomation during the night, severe 
lethargy, hypothermia, systemic bleeding, shock, dyspnea, tachycardia, thrombocytopenia, and 
glucocorticosteroid therapy. 
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1.2 IMMUNE RESPONSE AFTER ENVENOMATION 
 
1.2.1 IMMUNE SYSTEM: OVERVIEW 
 
The immune system contents two related systems: the innate system and the adaptative 
system.  
 
Epithelial barriers, resident neutrophils and macrophages, Natural Killer (NK) cells, 
polyreactive antibodies and the alternative pathway of the complement system provide innate 
immunity defences. Innate immunity response is relatively non-specific, provide instant 
defence but relatively weak and short one. Recognition of pathogen is mediated by 
transmembrane proteins known as toll-like receptors (TLRs). The innate immunity is provided 
by phagocytes (e.g. polymorphonuclear neutrophils PMN and resident macrophages), 
continuously present, rapidly activated and nonspecific in targeting pathogens. They detect and 
recognize non-specific pathogens, produce cytokines (such as IL-6, IL-1, TNF-α) that initiate 
the innate and the adaptative immune response and allow the recruitment of PMN to the site of 
infection, to finally phagocytize and kill the pathogen. Innate immunity is the immune response 
involved in envenomation.  Dendritic cells, which are Antigen Presenting Cells (APC), make 
the link between innate and adaptative immunity and transport antigen from primary site of 
infection to secondary lymphoid tissue.  
 
After the antigen recognition, allowing by the ACP, T lymphocytes multiply and 
differenciate in different types of cells, auxiliary lymphocytes able to produce cytokines and 
memory lymphocytes. B lymphocytes, after the action of cytokines secreted by auxiliary T 
lymphocytes, multiply and synthetize immunoglobulines.  Once T and B lymphocytes of the 
adaptative immune system are activated within the lymphoid tissue, they migrate to the site of 
antigen and neutralize it (Fig. VI) (Day Michael J, veterinary immunology book, 2011). 
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Figure VI. The innate and adaptive system (Day Michael J, Veterinary Immunology 
book, p11, 2011) 
 Once an antigen has been entering in the organism, the innate responses that include 
resident neutrophils and macrophages, NK cell, polyreactive antibodies and the alternative 
pathway of the complement system, provide innate immunity defences. Dendritic cells realize 
the transition to the adaptive system by transporting the antigen from primary site of infection 
to secondary lymphoid tissue. B and T lymphocytes are activated within the lymphoid tissue 
and then migrate to the site of antigen in order to neutralize it. 
NK= Natural Killer, T= Lymphocyte T, B= Lymphocyte B 	  	  
1.2.2 MAIN CARACTERISTICS OF THE INFLAMMATORY RESPONSE 
 
The aim of the inflammatory response is to neutralize the pathogen, contain it, 
prevent its systemic spread and promote tissue repair once the pathogen is eliminated. At the 
site of inflammation, a complex network of soluble inflammatory mediators is released. 
These mediators include the initiating alarmins, histamines (derived from mast cells and a 
potent vasodilatator), chemokines (involved in the recruitment of leucocytes from the 
bloodstream) and cytokines (involved in the recruitment and activation of leucocytes), 
molecules of the alternative pathway of complement, coagulation factors and the vasoactive 
lipids (eicosanoids). The eicosanoids are derived from arachidonic acid released from 
phospholipids of damaged cell membranes by the action of phospholipases. Arachidonic 
acid may be converted to leukotrienes (leukotriene B4) by the action of lipooxygenases, or 
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to a range of prostaglandins (prostaglandin E2), thromboxanes (thromboxane A2) and 
prostacyclins (prostaglandins I2) by the cyclooxygenases (COX-1 and COX-2) (Day 
Michael J, Veterinary  Immunology book, 2011). 
 
In addition to local tissue inflammation, systemic signs of illness may accompany the 
inflammation. This effect largely relates to the release of a series of proinflammatory cytokines 
from activated macrophages. These include interleukin 1 (IL-1), interleukine 6 (IL-6) and 
tumor necrosis factor alpha (TNF-α). They interact directly with nerve cells in damaged tissue 
and are absorbed into the bloodstream, where they are able to access the brain to bind receptor 
molecules that mediate pyrexia, lethargy, and anorexia. These circulating cytokines also 
stimulate the liver’s production of a collection of acute phase proteins such as C-reactive 
protein (CRP) promoting phagocytosis, serum amyloid A (SAA) acting as a leucocyte 
chemoattractant and having an immunosuppressive function.  
 
The final stage of the inflammatory response is tissue repair. Macrophages phagocytize 
target by generating nitric oxide (NO) from arginine (M1 cells) or by generating ornithine (M2 
cells). M2 macrophages produce fibroblasts and blood vessels including the cytokine 
transforming growth factors (TGF)-β, which promote the deposition of collagen and the growth 
of new vessels replacing areas of necrotic tissue  (Day Michael J., Veterinary Immunology 
book, 2011). 
 
1.2.2.1 Acute inflammation  	  
Acute inflammation begins within a few minutes after tissue damage and is characterized 
by the five cardinal signs of inflammation: pain, swelling, heat, redness and loss of function. 
Neutrophils migrate in the first few hours following the acute inflammatory response. In 
parallel, the stretching of the vessel wall initiates coagulation involving the platelets and 
coagulation factors. The aim of this mechanism is to prevent spread of pathogens into the 
bloodstream. Finally, the organism is phagocytized and destroyed by the respiratory burst or by 
lyzsosomal enzymes (Day Michael J, Veterinary Immunology book, 2011). 
 
1.2.2.2 Chronic inflammation 	  
Chronic inflammation begins between 24h and 48h after the initiating insult and is 
characterized by the recruitment of blood monocytes into the tissue. Although macrophages are 
less quickly recruited than neutrophils involved in the innate immunity, they are more potent, 
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have a longer life span and a role in tissue repair by phagocytosing the debris left after 
apoptosis of neutrophils (Day Michael J., Veterinary Immunology book, 2011).  	  	  
1.2.2.3 Complement system 
 
The complement system is composed of a serie of approximately thirty plasma proteins. 
There are four complement pathways interacting sequentially in order to form an enzymatic 
cascade: classical, alternative, lectin, and terminal pathways. Classical and alternative pathways 
lead to the final production of complement factor C3b. The lectin pathway interacts with the 
classical system. The terminal pathway uses the factor C3b and leads to cell lysis, 
inflammation, opsonisation and interaction with other pathways (Fig. VII). 
 
 
Figure VII. The four complement pathways and their interaction (Day Michael J., 
Veterinary Immunology book, p31, 2011) 	  
Once the terminal complement is activated, thousands of MAC (Membrane Attack 
Complex) are generated within the membrane of the target cells and lead to cytolysis. The 
second major consequence of terminal complement activation is the generation of fragments, 
especially C3a, C3b and C5a, also named anaphylatoxins or chemoattractants. These 
anaphylatoxins have key roles in the tissue inflammatory response via several mechanisms. 
They are responsible for vessels vasodilation allowing vascular fluid and oedema, which may 
further dilute toxins produced locally. It also results in a local influx antibody and complement, 
participating in a local immune response in conjunction with mast cell degranulation. C3a and 
C5a activate neutrophils in order to enhance the phagocytic action and the release of 
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inflammatory mediators. A chemotactic gradient with the highest concentration of complement 
factors at the site where they were produced, allows an influx of these cells to the location of 
the antigen (Fig.VIII). 
 
 In some circumstances, the actions of C3a and C5a may cross the border between a 
useful role in local inflammation and a pathological inflammatory response. These molecules 
may cause massive mast cells degranulation and further expand the tissue inflammatory 
response (Day Michael J, Veterinary Immunology book, 2011). 	  	  	  
	  
 
Figure VIII. Roles of complement factors C3a and C5a (Day Michael J, Veterinary 
Immunology book, p35, 2011) 
The interaction between antigen and antibody activates the production of C3a and C5a 
that stimulates smooth muscle contraction, mast cell degranulation, neutrophil activation and 
vasodilatation of vessels responsible for local oedema and local infux antibody and 
complement (local immune response). The gradient of complement factors’ concentration 
allows the influx of cells to the initial site of the antigen. 
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1.2.2.4 Involvement of cytokines in acute inflammatory responses 
 
Numerous cytokines are involved in the inflammatory responses. Some of them will be 
discussed in this paragraph (Fig. XIII). 
1.2.2.4.1 Cytokine overview 
 
Cytokines are believed to be mediators that regulate all the phases of the inflammatory 
response and the outcome of the response is determined by their network (Arend and Gabay, 
2004). Some cytokines may circulate systemically and have distant actions (endocrine). They 
are therefore one of the key means of communication between cells of the immune system 
(ACPs, T and B lymphocytes, NK cells) and between immune cells and other cells from the 
body.  
Any single cell may produce a large number of cytokines and numerous cytokines may 
act on one target cell. Cytokines have multiple actions depending on the immunological 
circumstances and have different roles, from involvement in haemopoiesis and development of 
B and T lymphocytes, activation or suppression of immune cells to pro-inflammatory effects. It 
is possible to detect these cytokines by both cytokine gene transcriptions in tissue thanks to 
quantitative real-time reverse transcriptase-polymease chain reaction (RT-PCR) and the 
presence of cytokine protein in tissue or fluid samples using ELISA or complex bead-based 
multiplex assays (Khan 2008). 
 
1.2.2.4.2 Multifunctional cytokines 
 
IL-1, IL-6 and TNF-α are typical examples of multifunctional cytokines involved in the 
regulation of the immune response and inflammation. They show a wide variety of biological 
functions (Tabl. VIII) but each has also a particular characteristic function. IL-1 and TNF-α are 
considered as early or “alarm cytokines” with pleiotropic activities and the induction of a 
second wave of cytokines (IL-6, chemokines, IL-1 and TNF-α) and non cytokines mediators to 
amplify the inflammatory response.  
 
IL-1, IL-6 and TNF-α are considered the most important pro-inflammatory cytokines, 
responsible for the initiation and propagation of the inflammatory response. IL-1 and IL-6 act 
on the synthesis of some Acute Phase Proteins (APPs), and are able to induce IL-6 release by 
fibroblasts. These interleukines induce fever, expression of adhesion molecules, hepatic 
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proteins, and T and B cells activation (Akira et al. 1990). TNF-α is known for its tumoricidal 
activities.  All these cytokines are able to regulate the immune response, heamatopoiesis and 
inflammatory reactions (Akira et al. 1990).  
IL-6 seems to play the most important role in the regulation of APPs. Indeed, it is the 
only cytokine able to stimulate the full spectrum of APP such as CRP synthesis in human 
hepatocytes (Castell et al. 1989). This cytokine is also recognized to be implicated in various 
inflammatory diseases such as rheumatoid arthritis, insulitis, thyroiditis and glomerulonephritis 
(Akira et al. 1990).  
 
Interferon-α,β (IFN-α,β) are known for their antiviral, antibacterial, antifungal and 
antitumora effects. They also have a role in the immunomodulation of antibody production and 
can induce autoimmune and inflammatory reactions. In addition, IFN-β enhances macrophage 
production of several cytokines such as IL-1 and TNF (Paul William E., 1989). 
 
IL-8 has a key role in attracting and activating neutrophils and has been described to be 
the main cause of this influx in many conditions (infection, ischemia, trauma, homeostasis 
damaging). Due to its long-lasting chemoattractant effects, it is thought to persist a long time in 
active form in tissue where it is released (Baggiolini and Clark-Lewis 1992). 
 
 
Table VIII. Properties of IL-1, IL-6 and TNF-alpha (from Akira et al. 1990) 
Interleukin IL-1 IL-6 TNF- α 
Producers Macrophages, 
keratinocytes, 
endothelial cells, B cells, 
astrocytes, fibroblasts 
Macrophages, T cells, B cells, 
keratinocytes, endothelial 
cells, fibroblasts, astrocytes, 
mesangial cells, bone marrow 
stroma cells 
Macrophages, T cells, 
NK cells 
Biological 
activities 
Induction of: 
   PGE2 synthesis 
   Growth of fibroblasts 
   Bone resorption 
   ICAM-1 expression 
   Fever 
   Sleep 
   Anorexia 
   Synthesis of    
collagenase 
    Growth and 
differentiation of T and 
B cells 
Induction of: 
B cell differentiation 
Plasmocytoma growth 
Acute phase protein   
synthesis 
Macrophage differentiation 
Hematopoietic stem cell 
growth 
Maturation of 
megakaryocytes 
Neural cell differentiation 
Mesangial cell growth 
Myeloid leukemic cell 
differentiation 
Tumoricidal activity 
Inhibition of     
lipoprotein lipase 
Induction of: 
Bone resorption 
Myeloid leukemic 
cell differentiation 
Procoagulant activity  
Growth and 
differentiation of B 
cells 
ICAM-1 expression 
 
Producers and biological activities of one of the most pro-inflammatory cytokines  
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1.2.2.4.3 Cytokines and acute Phase Protein synthesis 	  
The acute phase response is a non-specific inflammatory response that occurs shortly 
after any tissue injuries. It is characterized by changes in the concentrations of plasma proteins, 
called Acute Phase Proteins (APPs): negative APPs (e.g. albumin or transferrin) have decreased 
concentration levels while positive APPs (e.g. C-reactive protein [CRP], serum amyloid A 
[SAA], haptoglobin [Hp], alpha-1-acid glycoprotein [AGP], ceruloplasmin (Cp), and 
fibrinogen) have increased concentration levels. APPs are involved in the regulation of the 
immune response, the inflammation, and the protection against the infection, and there are also 
involved in the repair and recovery of damaged tissue. A single APP can have both a pro- and 
anti-inflammatory effect, with a specific blance between the two functions. Most of the positive 
APPs are glycoproteins synthesized mainly by hepatocytes. Pro-inflammatory cytokines act in 
an hormone-like manner, being generated at the inflammation site and transported to the liver 
via the bloodstream to induce APP synthesis (Cerón, Eckersall, and Martínez-Subiela 2005; 
Akira et al. 1990). 	  
1.2.2.4.4 Cytokines and recruitment of leukocytes to inflammatory sites 
 
The chemoattractant cytokines or chemokines are involved in the recruitment of 
leucocytes from blood into tissue (Fig IX.). 
The main chemokine responsible for recruiting monocytes to inflammatory sites is the 
chemokine MCP-1. It has been demonstrated that this chemokine is involved in mediating early 
monocyte recruitment in murine peritonitis. Its rapid release by macrophages and also 
mesothelial cells allows immediate recruitment of monocytes from the circulation 1.5 to 2 
hours after the stimulus (Henderson 2003). In addition to its chemoattractant activity, MCP-1 is 
also able to activate other cytokines (e.g. IL-l, IL-6) and enhance calcium flux and respiratory 
burst (Cavaillon 1994). 
IL-1 and TNF-α induce the expression of adhesion molecules, such as the Intercellular 
Adhesion Molecule 1 (ICAM-1) and the Platelet Endothelial Cell Adhesion Molecule 1 
(PECAM-1) on endothelial cells. Thus, the binding between leukocytes and endothelial cells 
stop the rolling of leukocytes and allow them to transmigrate into the affected tissue (Downey 
1994). IL-1 and TNF-α also induce the secretion of chemokines, which further stimulate 
leukocytosis and the migration of neutrophils to the inflammation site. After penetration into 
the inflamed site, numerous cytokines are then produced by the activated leukocytes, which 
amplifies the inflammatory response (Akira et al. 1990). They have numerous other activities 
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such as osteoclast activation factor, cartilage degradation, fibroplasia and angiogenesis, 
adipocyte lipolysis, cachexia, etc. (Paul William E., 1989, p655). 
 
 
Figure IX. Leukocytes adhesion and involvement of chemokines (Day Michael J, 
Veterinary Immunology book, p63, 2011) 
The first step to recruit leukocytes to the inflamed tissue is the tethering or rolling of 
polynuclear neutrophils on the endothelium of postcapillary venules. This step is made thanks 
to the binding between E-selectin (selectin family of adhesion molecule), expressed on the 
vascular endothelium and CD15, and expressed on the surface of neutrophiles. Then, 
chemokines and signaling molecules allow leukocytes to trigger to the vascular endothelium. A 
high affinity interaction between integrins on the neutrophil (CR3) and ICAMs on the 
endothelial cell allows the neutrophil to transmigrate into the affected tissue. 
LFA-1= leucocyte function antigen-1, ICAM-1= intercellular adhesion molecule-1, 
CR3=complement receptor type 3,  
 
1.2.2.4.5 Role of cytokines, neutrophil activity and neutrophil apoptosis: 
protective or deleterious inflammatory response 
 
Once neutrophils have transmigrated into the affected tissue, they are able to combat the 
pathogene by several mechanisms such as the production of toxic oxygen radicals, the release 
of antimicrobial and lytic enzymes and the release of granule proteins (Bordon et al. 2013). 
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Moreover, they are also able to synthetize and release various cytokines (Marco Antonio 
Cassatella 1999; Marco A. Cassatella 2013).  
Neutrophils have a very short lifetime. To maintain the cellular homeostasis, the death of 
neutrophils occurs in the absence of extracellular stimuli. Neutropenia can be caused by a rise 
in neutrophil death, which can increase bacterial and fungal infections. On the other hand, 
neutrophilia can be caused by delayed neutrophil death, which is associated with an increased 
inflammation after infection. Thus, maintaining appropriate neutrophil numbers or neutrophil 
homeostasis is critical during infection and/or inflammation. In the resolution of inflammation, 
the accumulated neutrophils need to be removed (Bordon et al. 2013).  
 
The apoptosis plays a major role in eliminating neutrophils, controlling the duration and 
intensity of the inflammatory response and therefore the extent of neutrophil-mediated tissue 
damage (Fig.X). Many components may delay the apoptosis of neutrophils, leading to 
secondary necrosis and the release of pro-inflammatory mediators from the phagocyte which 
may further delay the inflammatory response (Simon 2003; Heasman et al. 2003). 
Glucocorticoids play a role in the resolution of inflammation since they facilitate clearance of 
apoptotic cells (Heasman et al. 2003). 
 
Thus, there is a relative balance between the need for inflammation to stimulate repair 
and the need to limit inflammation because of the additional tissue damage (Butterfield, Best, 
and Merrick 2006).  
 
In the example of the pneumonia in humans, when this balance is respected, the acute 
inflammation response is protective and self-limited. Once the infection is controlled, cytokines 
also act to restore homeostasis, including the modulation of neutrophil apoptosis (Haslett 
1999). On the other hand, a cytokine storm results in a deleterious inflammation and poor 
clinical outcomes (fig. XI) (Bordon et al. 2013) 
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Figure X. Inflammatory response and role of neutrophils (Simon 2003).  
Once the pathogen is recognized by TLR-expressing cells, pro-inflammatory cytokines 
are generated. Neutrophils are recruited to the site of inflammation and contribute to the 
elimination of pathogens (1) and also regulate the inflammatory response by the generation of 
cytokines (2). As neutrophils can cause tissu damage, their numbers need to be regulated.  
TLR= Toll-like receptor 
 
 
 
Figure XI. Example of cytokine storm and deleterious inflammation in a case of 
pneumonia (Bordon et al. 2013) 
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1.2.2.4.6 Fever induction 
 
Fever is a part of the acute phase reaction representing an adaptive mechanism against 
infection: inhibition of bacterial growth, stimulation of APP synthesis, increased bactericidal 
activities of neutrophils and macrophages (Saper and Breder 1994). A multi-pathway 
mechanism was suggested for the induction of fever – including pyrogenic cytokines such as 
TNF, IL-1, IL-6, and IFN acting on CNS and inducing PGD (Netea, Kullberg, and Van der 
Meer 2000) 
 
Figure XII. Summary of numerous activities of IL-1, IL-6 and TNF and interaction 
between cytokines (modified from Paul William E., p656, 1989).  
IL= Interleukin, TNF= Tumor necrosis factor, MCP-1= Monocyte chemotactic protein, ICAM-
1= intercellular adhesion molecule-1, PECAM= Platelet Endothelial Cell Adhesion Molecule 1  
Dotted arrows represent the stimulation of synthesis. 
 
 
Differentiates     
hematopoietic 
     precursor cells !Stimulates pituitary ACTH and adrenal  glucocorticoids !
!!!!!!! !!
IL#6%Activate!NK!cells!Neutrophil!apoptosis!Monocyte!recruitment!Anti6inflammatory!activities!
IL#1%Neutrophil!infiltration!Oedema!Mononuclear!infiltration!!!
TNF%Neutrophil!activation!Tumor!necrosis!!
APP!synthesis,!acute!phase!response!B!and!T!lymphocytes!activation!Endogenous!pyrogen!!
ICAM-1, PECAM-1 induction: 
endothelial cell adhesiveness 
Neutrophilia 
Osteoclast activation factor 
Cartilage degradation, fibroplasia and 
angiogenesis, adipocyte lipolysis, 
cachexia 
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1.2.2.5 Interleukin-6: principal characteristics and interests 
 
IL-6 is produced by many cells including macrophages, T cells, B cells, fibroblasts, 
endothelial cells, astrocytes, mesangial cells, bone marrow stroma cells. It was originally 
known as a T cell derived lymphokine that induced antibody production in B cells. Thus, its 
primary role is to induce IgM, IgA and IgG production. IL-6 also acts on T-cells by the 
stimulation of another cytokine production (IL-2) (Akira et al. 1990). Since it is able to increase 
the secreation of adrenocorticotropic hormones and glucocorticoids, the rise of IL-6 could 
explain lymphopenia and leucocytosis (Paul William E., p656, 1989). 	  
1.2.2.5.1 Pro and anti-inflammatory activities, hematopoiesis activity 
 
As said previously (part 1.2.2.4.2), IL-6 acts as an important pro-inflammatory cytokine 
by activating the immune system (APPs stimulation). Acute inflammation is characterized by 
an initial infiltration of neutrophils. IL-6, in conjunction with chemokines produced by 
endothelial cells and vascular elements, leads to the attraction of neutrophils in the initial phase 
(Scheller et al. 2011). 
 
Moreover, there are several evidences that IL-6 is implied in the shift from neutrophils to 
monocytes in inflammation. Neutrophils show a high interest in an organism’s defense against 
injury thanks to its capacity to synthesize oxygen metabolites and various enzymes. However, 
they might be toxic for surrounding tissue and might induce inflammatory diseases. Therefore 
they have to be rapidly negatively regulated (part. 1.2.2.4.5). IL-6 induces neutrophil apoptosis 
and the phagocytosis of apoptotic neutrophils induced MCP-1 (monocyte chemotactic protein) 
production by macrophages. Then, both neutrophil elimination and chemokine shift lead to 
monocytes recruitment (Fig.XIII). Thus, IL-6 plays a protective role by decreasing neutrophil 
and favoring monocytes recruitment, allowing the initiation of an immune response (Kaplanski 
et al. 2003). In addition of its role in the acute neutrophil infiltration’s resolution, IL-6 is also 
necessary for the recruitment and the anti-apoptosis of T lymphocytes as well as for B and T 
cells’ differentiation by acting in the adaptive system – that we will not develop here (Scheller 
et al. 2011).  
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Figure XIII. Implication of IL-6 in the transition from neutrophil to monocyte 
recruitment (Kaplanski et al. 2003) 
Endothelial activation by pro-inflammatory molecules leads to PAF, IL-8, leuko-
endothelial adhesion molecule (ICAM-1) and IL-6 expression (blue arrow). Chemoattractants 
recruit neutrophils and induce IL-6-Rα shedding from their membranes (red arrow). The 
combination of IL-6 with its receptors IL-6-Rα enables binding to gp130 on endothelial cell 
membrane (black arrow) and increases both IL-6 and MCP-1 endothelial cell production 
(green arrow) but not IL-8, favoring a transition from neutrophil to monocyte recruitment. 
ICAM=intercellular adhesion molecule; IL=interleukin; MCP=monocyte chemo-tactic 
protein; PAF=platelet activating factor; sIL-6-R-soluble IL-6 receptor; VCAM=vascular-cell 
adhesion molecule.  
 Another interesting role of IL-6 is its function of thrombopoietin. Indeed, neutralized 
thrombopoietin in mice treated with IL-6 showed an enhanced hepatic thrombopoietin mRNA 
expression and an increased thrombopoietin level. This study suggests that IL-6 induces 
thrombocytosis through thrombopoietin (Kaser et al. 2001). 
Reports on mice studies have also showed that IL-6 presents anti-inflammatory (or 
regenerative) properties by inducing the regeneration of epithelial cells after DSS (dextran, 
sodium, sulfate) induced damage (Scheller et al. 2011). 	  
1.2.2.5.2 Interleukin-6: beneficial and deleterious effects 
 
The severity of diseases has been associated with excesses of both pro- and anti-
inflammatory cytokines, particularly IL-6 and IL-10. Indeed, the pro-inflammatory cytokine 
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response is normally regulated by the anti-inflammatory components of the immune system. 
However, if this balance in not respected, deleterious effects may result (Bordon et al. 2013).  
In several studies, the presence of IL-6 was determined to be either positive or 
detrimental (Fig. XIV). Indeed, IL-6 seemed to be particularly important in controlling 
infectious diseases associated with intracellular parasites (Trypanosoma cruzi) and gram-
negative bacteria (Escherichia Coli) - especially since it allows the recruitment of neutrophils 
(Dalrymple et al. 1996; Gao and Pereira 2002). 
Nevertheless, it is recognized that a persistent elevation of cytokines is associated with a 
higher risk of death, and mortality seems to be correlated with the ratio of IL-6 to IL-10 
(Bordon et al. 2013). Indeed, IL-6  was mostly considered as deleterious and was shown to be a 
marker of disease severity in sepsis and an association between IL-6 levels and poor outcome 
was found in patients with sepsis (Hack et al. 1989; Remick et al. 2005). Moreover, it was 
proved that the use of IL-6 antibodies contributes to improve survival in sepsis induced by 
cecal ligation/puncture in mice. Even if no potential hemodynamic effects (cardiovascular 
alteration) have been associated to IL-6 on dogs (Preiser et al. 1991), IL-6 was shown to 
increase C5a receptor, known to have deleterious effects during the early phases of sepsis. The 
blockage of IL-6 results in a significantly reduced expression of C5aR production in lungs, 
livers, kidneys, and heart, leading to greatly improved survival (Riedemann et al. 2003). 
 
 
 
 
 
 
 
 
 
 
 Figure	   XIV.	   Main activities of IL-6. Simplified figure of beneficial versus deleterious 
effects of IL-6.  
IL-6 has pro- and anti-inflammatory activities involved in the activation of the immune 
system and in the control of infectious diseases. IL-6 is overall known for its deleterious effects. 
Deleterious effects are observed in case of persistent elevation of cytokines (unachieved or 
altered balance between pro- and anti-inflammatory components) and through the increase in 
C5aR, associated with higher mortality and poor prognosis in sepsis. 
Pro and anti-inflammatory activities:  
 
- Recruitment of mononuclear cells 
- Neutrophil apoptosis and phagocytosis of 
apoptotic neutrophils 
- Inhibition of T cells apoptosis 
- B and T cells differentiation  
- Regeneration of epithelial cells 
 
à Stimulate the immune system, involved in 
controlling infectious diseases 
 
 
 
- Persistent elevation (uncontrolled inflammatory 
response) 
- Increased expression of C5aR 
 
 
 
 
à Higher risk of dying, negative prognostic factor 
for outcome in sepsis 
Beneficial effects of IL-6  Deleterious effects of IL-6  
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1.2.2.5.3 Interleukin-6: cytokine measurement in body fluids 
 
Several factors can influence cytokine measurement in body fluids (Fig.XV).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure XV. Factors affecting cytokine measurement in body fluids (Bienvenu et al. 
2000). 
Autoantibodies are very similar to the antibody developed by the immune assay and can 
bind to cytokine. All cytokine soluble receptors represent a potential source of interference in 
immunoassays. Circadian rhythms were reported for IL-6 (with a peak in the morning). 
Specific receptor antagonist (IL-1-RA) can interfere with IL-6. Non-specific inhibitors, 
represented by plasma proteins, with α2- macroglobulin, can bind to cytokine but with a low 
affinity. 
 IL-1-RA=Interleukin 1 rheumatoid arthritis, TNF-a=Tumor necrosis factor alpha, IL-
1=Interleukin 1, IL-6R=Interleukin 6 receptor. 
 
To measure cytokines, two methods are described: bioassays, based on various biological 
response, and immunoassay, based on the specific use of monoclonal antibodies. Due to their 
high specificity, immunoassays have rapidly become the reference. Radioimmunoassays 
(essentially immunoradiometric assay) or ELISA were developed using a first monoclonal 
antibody to bind the cytokine, and a second antibody (monoclonal or polyclonal) for the 
revelation. Many commercial kits are now available with ELISA microplate format. The 
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detection limit of the majority of cytokine kits is around 5pg/ml, i.e. greater than the circulating 
concentrations of many cytokines not only in physiological, but also, sometimes, in 
pathological conditions (Bienvenu et al. 2000). 
 
1.2.2.5.4 Interleukin-6: interests of investigation 
 
The half-life of cytokines is very short (usually less than ten minutes), leading therefore 
to brief peaks in blood (Bienvenu et al. 2000).  Low concentrations of IL-1 and TNF are 
sufficient to activate inflammatory response. As a result, it can be difficult to detect systemic 
IL-1 and TNF in the serum, while IL-6 levels are quite abundant. Moreover, as IL-6 is induced 
by IL-1 and TNF rather than by direct effects, it is also an evidence of IL-1 and TNF 
productions (Voronov, Apte, and Sofer 1999). 
 
The proinflammatory cytokine interleukin-6 (IL-6) has a longer plasma half-life than 
tumor necrosis factor alpha (TNF-α) or interleukin-1-beta have (Rau et al. 2007). The kinetic of 
IL-6 was measured by ELISA in a canine model of sepsis induced by endotoxin. IL-6 levels 
peaked at 3h and changes in serum IL-6 remained increased during 24h (Song et al. 2012). 
Plasma interleukin-6 response is known to be predictive for severity and mortality in 
canine systemic inflammatory response syndrome and sepsis. It is considered to be a good 
marker of the severity of a systemic bacterial infection and thus can reasonably be considered 
as a valuable biomarker, providing information on the pathogenesis, diagnosis, and prognosis 
of systemic inflammatory response (Rau et al., 2007). 
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1.2.3 IMMUNE SYSTEMIC RESPONSE TOWARDS SNAKE VENOM 
 
The immune response towards snake venom depends on several factors such as the 
structure and the concentration of the venom toxins or the dose of venom that is administered. 
Most studies on the immune systemic response towards snake venom are on Viperidae snakes. 
Thus, venom components will be further compared. 
 
1.2.3.1 Evidence and mechanisms of inflammation induced in snake 
envenomation 
 
Inflammation is a common finding in snake envenomation with several evidences: 
oedema, inflammatory cell infiltrate, and inflammatory mediators. 
1.2.3.1.1 Oedema  
 
An oedema, as a result of remodelling in vascular permeability, is the first local evidence 
of an inflammatory process implication in snake envenomation. In mice envenomed by 
Viperidae, an oedema develops over the first thirty minutes after venom injection, seems to 
reach a peak one or two hours post venom injection according to the authors, and then 
decreases (Picolo et al. 2002; Moreira et al. 2012). In a study of dogs envenomed by Vipera 
palaestinae, 99.6% of dogs showed local swelling and oedema (Segev et al. 2004). It was 
suggested that the oedema formation is the result of vasoactive components induced by the 
venom (Moreira et al. 2012). 
 
1.2.3.1.2 Influx of leucocytes 
 
A second common process of inflammatory response to envenomation is the influx of 
leucocytes, especially neutrophils, to the site of venom injection in order to contain and 
eliminate the pathogen (Part 1.2.2). In vivo on mice, this was described in the peritoneal cavity 
of mice after injection of Bothrops asper and Bothrops atrox venoms (Viperidae family). 
According to the authors, an increased of leukocytes was lasting from 1h to 48h after venom 
injection, reaching a peak between 4h and 6h ( Moreira et al. 2012; Escocard et al. 2006; Stella 
R Zamuner et al. 2001).  
At the beginning (3h to 24h), the predominant cells among these leucocytes observed 
were neutrophils (Stella R Zamuner et al. 2001), although another peak of neutrophils was also 
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reported 48h post venom injection (Escocard et al. 2006). Mononuclear leukocytes seem to 
appear later (48h). 
 In response to the presence of the pathogens in snake envenomation, neutrophils were 
shown to regulate the release of inflammatory mediators (cytokines and chemokines) and 
induce phagocytosis, associated with an enhanced expression of iNOS (inducible nitric oxide 
synthase) by macrophages (Escocard et al. 2006; Stella R Zamuner et al. 2001). Neutrophils do 
not seem to play a role in local tissue damage such as myonecrosis or haemorrhage but may 
contribute to delay the regenerative response in muscles (Teixeira et al. 2003). 
 
1.2.3.1.3 Inflammatory mediators 
 
Cytokines and complement play an important role in this inflammatory process which 
were specifically described in vipers (Bothrops asper, Vipera russelli, Ammodytes, 
Meridionalis, Aspis), rattlelsnakes (Crotalus) and Elapids (Farsky et al. 2000; Stella R. 
Zamuner et al. 2005; Langhorn et al. 2014; Santhosh et al. 2013; Szold et al. 2001; Tambourgi 
et al. 1994). Most studies concern snake venom of Viperidae family. 
Acute phase protein: C-reactive protein (CRP) 
According to Brandeker et al. (2015), in a study on dogs envenomation by Vipera berus, 
CRP concentration was increased in 80% of dogs. A correlation between degree of oedema 
swelling and CRP concentration was observed, bringing evidence of inflammation resulting 
from the envenomation. CRP concentration was often in the normal reference range at 
admission of the envenomed dogs despite the presence of swelling, but it was highly increased 
24h later.  
Eicosanoids and cytokines  
Interleukin 6 (IL-6), interleukin 1B (IL-1B), tumor necrosis factor (TNF-α), interferon-γ 
(IFN-γ), chemokine MCP-1 and eicosanoids (prostaglandins PGD2, PGE2, thromboxane TXA2 
and leucotrienes LTB4), were found to have increased concentrations at different time, in the 
serum sample and in the site of injection of Bothrops venom in mice (Rucavado et al. 2002; 
Petricevich et al. 2000; Stella R. Zamuner et al. 2005; Moreira et al. 2012). 
 	  The molecules which concentrations increased the earliest are some eicosanoids, thought 
to be involved in the influx of leucocytes, with higher PGD2 level at 30min after venom 
injection. Moreover, the observation of cyclooxygenases COX-2 level’s increase between 1h 
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and 4h after Bothrops asper venom (BaV). It is thought that COX-1 initiates the production of 
eicosanoids, followed by the induction of COX-2 to stimulate PGDs production in the late 
periods of inflammatory process induced by the envenomation (Moreira et al. 2007). 	  The concentration of IL-6 also increased in the early stages (1h to 3-6h post venom 
administration according to the authors) (Stella R. Zamuner et al. 2005; Moreira et al. 2012; 
Lomonte, Tarkowski, and Hanson 1993).  
TNF-α levels were found higher 1h after injection of BaV, and no detectable production 
was observed at the later time intervals studied. MCP-1 levels increased between 1h and 8h 
with a peak at 4h (Moreira et al. 2012). IFN-γ levels also increased after Bothrops venom 
injection (Stella R Zamuner et al. 2001). Numerous other cytokines and eicosanoids are thought 
to be involved in the infiltration of leukocytes to the injection site, associated with neutrophil 
activation and the activation of adhesion molecules on endothelial cells (Stella R Zamuner et 
al., 2005; C. Teixeira et al. 2009). 
Nitric Oxide production 
The mechanism by which snake venom induces the production of Nitric Oxide (NO) was 
not well described (Petricevich et al. 2000) until Zammuner et al. strongly suggested a role for 
IFN-γ as a mediator of macrophage iNOS synthesis induction by the venom. NO was assumed 
to be involved in tissue damage through its ability to form peroxynitrite after reaction with 
locally generated superoxide anions. NO is also involved in hypotension observed on snake 
envenomation (Stella R Zamuner et al. 2001).  
 
Activation of the complement system 
In-vitro studies, where Bothrops snake venom was administrated to human plasma, have 
shown activation of the complement cascade (C3a, C4a, C5a fragments) (Pidde-Queiroz et al. 
2010; Farsky et al. 2000). By pre-incubating neutrophils with anti-rat C5a receptor, a dose-
dependent inhibition of the migration of neutrophils was observed, suggesting that C5a is 
involved in the in-vitro neutrophils recruitment. Moreover, in C5a-deficient mice, no migration 
of neutrophils was observed which lead the authors to the conclusion that C5a is also involved 
in in-vivo neutrophils recruitment and is an important component of the inflammatory response 
to envenomation (Farsky et al. 2000). In accordance with this study, Rodrigues (2004) 
indicated that the complement system is involved in neutrophiles accumulation, but not in the 
hemorrhage, at the site of venom components injection. It was shown in some Elapids (genera 
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Micrurus and Naja) that their venoms contain components able to activate the complement 
system in a dose related way (Tambourgi et al. 1994).  
 
 
 
 
 
 
 
 
 
 
 	  	  
 
 
 
 
 
Figure XVI. Effects of snake venom on the production and the activation of mediators 
(modified from Luna, da Silva, and Pereira 2011). 
IL-6=Interleukin 6, IL-1=Interleukin 1B, TNFα=Tumor necrosis factor α, IFN-
γ=interferon-γ, MCP-1=chemokine, PGD2=Prostaglandin D2, PGE2=Prostaglandin E2, 
TXA2= Thromboxane A2, LTB4= Leucotrienes B4 
 
 
1.2.3.2 Venom components acting in the inflammatory response 
 
As seen previously, snake venom are composed in majority with toxic proteins, lipids and 
other molecules which act as immunogenic components and induce toxic effects (Leon et al. 
2011). It has been shown that various venom components such as phospholipase A2 (PLA2) 
and snake venom metalloproteinases (SVMP) can cause the release of inflammatory mediators 
(Cher et al. 2003; Birrell et al. 2007). The role of these components in the inflammatory 
process has been particularly studied in the literature (fig. XVIII).  
Snake venom 
Acute phase 
protein, 
eicosanoids and 
cytokines 
synthesis  
 
 
NO production 
 
Activation of the 
complement 
system 
 
- C3a, C4a, C5a 
- Neutrophil 
recruitment 
 
 
Tissue damage 
Hypotension 
 
IL-6, IL-1, TNFα IFN-
γ 
MCP-1 
PGD2, PGE2, TXA2, 
LTB4 
	  70	  
Role of metalloproteinases 
First of all, SVMP play many roles in the local tissue damage and pro-inflammatory 
process (Fig. XVIII). Besides their action on the haemostatic system (procoagulant effects, 
inhibition of platelets aggregation, haemorrhage, blister formation) (see part 1.1.2.2) and 
besides their role on myonecrosis and dermatonecrosis, metalloproteinases have both direct and 
indirect actions on the inflammatory response. Indeed, metalloproteinases of Bothrops asper 
venom, isolated and injected in mice are reported to induce oedema (Gutiérrez et al. 1995). 
They are able to activate the complement system, even though other mechanisms might be 
actors too (Farsky et al. 2000). SVMP are also involved in the release of inflammatory 
mediators (cytokines, TNF-α), which can further exacerbate the oedema formation by 
increasing the endothelial permeability (Rucavado et al. 2002). The extent of local necrosis 
after snakebite is highly affected by the release of cytokines induced by metalloproteinases. 
Chemotactic factors, important in the neutrophils recruitment during inflammation, were shown 
to be induced by metalloproteinases and complement activation (C5a), but did not imply other 
components such as PLA2 or myotoxins (Farsky et al. 2000). Part of metalloproteinases also 
activate endogenous non-haemorrhagic metalloproteines, called Matrix Metalloproteinases 
(MMPs), which are able to degrade the extracellular matrix (Rucavado et al. 2002). 
 
 
Figure XVII. Metalloproteinases and their roles in the pathogenesis of local tissue 
damage (Rucavado et al. 2002) 
            : Roles of metalloproteinases in the immune response and tissue damage 
MMPs= Matrix Metalloproteines; TNF-	  α= Tumor Necrosis Factor α 
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Role of PLA2  
PLA2s, important myotoxins of snake venom, have been isolated from Bothrops asper 
venom and their roles have been characterized in several studies (Fig.XVIII).  
First, PLA2s are thought to be other actors in the oedema formation (Chaves, Barboza, 
and Gutiérrez 1995; Milton M Kanashiro 2002; Zuliani et al. 2005). The rapid plasma 
extravasation (in the first 15 minutes after PLA2s administration), suggested the involvement 
of vasoactive mediators derived from mast cell granules (Zuliani et al. 2005). It was also 
reported that their action in oedema formation is in part related to damage in smooth muscle of 
lymphatic vessels (Mora et al., 2008) . 
Secondly, they are involved in myonecrosis events associated with higher CK level serum 
in mice, 1 hour after PLA2s injection, and damage in striated muscle cells too (Milton M 
Kanashiro 2002). 
Besides, an important influx of leukocytes with mainly neutrophils was observed 
following the administration of a certain dose of PLA2 of Bothrops asper venom. This influx 
of neutrophils was maximal 6 hours after PLA2 injection (Kanashiro et al., 2002) (Zuliani et al. 
2005). Since the treatment with anti adhesion molecules monoclonal antibodies decreased the 
neutrophil influx induced, the authors conclude that PLA2s also up-regulate the expression of 
cell adhesion molecules, involved in neutrophils recruitment (Zuliani et al. 2005). As seen 
previously, numerous mediators are involved in neutrophils recruitment. It was demonstrated 
that PLA2s up-regulate the eicosanoids levels (LTB4 and TXA2) and both PLA2s are able to 
induce an augmentation of IL-1 and IL-6 levels in the peritoneal fluid of mice after injection 
(Zuliani et al. 2005). Last, a study on potential actions of Crotalus venom on immune and 
neuroendocrine function showed that PLA2s were able to enhance plasma glucose, ACTH, 
corticosterone, and TNFα plasma levels and thus stimulate both hypothalamo pituitary adrenal 
axis and immune functions during the acute phase response of the inflammatory process 
(Chisari et al. 1998). 
 
Other venom components 
Other serine proteases (BpirSP27 and BpirSP41, from Bothrops asper venom) were 
described to play a role in the inflammatory response to snake envenomation. They may 
activate the complement pathway but play a minor role on the pro-inflammatory response by 
inducing only a small oedema formation and weak leucocytes recruitment (Menaldo et al. 
2013). 
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Figure XVIII. Schematic summary of the inflammatory action of a metalloproteinases 
and phospholipases A2 of Bothrops asper venom (C. Teixeira et al. 2009) 
Metalloproteinases and phospholipases A2 are thought to be the major components 
responsible for the inflammation response at the snakebite site. The venom is able to activate 
the complement system, responsible for leukocyte recruitment (activation, up-regulation of 
adhesion molecules, transmigration and chemotaxis). The venom also induces the expression of 
the iNOS and the consequent production of NO by leukocytes. The release of TNF-α seems to 
be related to expression nitric oxide whereas the other cytokines and eicosanoids are 
associated with induction of leukocytes recruitment. The venom up-regulates the expression of 
COX-2 by both macrophages and neutrophils, further source of eicosanoids in envenomed 
sites. 
BaP1=Bothrops asper Protein 1, COX=Cyclooxygenase, PGE=Prostaglandins E, 
TXA2=Thromboxane A2, LTE=Leukotriene E, IL-6=Interleukine 6, IL-1=Interleukine 1, TNF-
α=Tumor necrosis factor α, INF-γ=Interferon γ, NO=Nitric oxide, iNOS=Inducible Nitric 
Oxide Synthetase, LFA-1=Lymphocyte Function-Associated antigen-1, PECAM=Platelet 
Endothelial Cell Adhesion Molecule 
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1.2.3.3 Venom components and inflammation in Elapids 
 
 
The immune systemic response towards snake venom was described mainly in Viperidae. 
As said previously, Elapid venom contains mainly neurotoxins, prothrombin activators, and 
PLA2s. Neurotoxins and prothrombin activators are more implicated in neurological effects 
and coagulopathy and do not seem to be implied in the inflammatory response. PLA2s seem to 
be the main venom component responsible for inflammation in Elapids. SVMP was also 
identified in some Elapid species but remains predominantly described in Viperidae. 
Nevertheless, it seems that some clinical effects attributed previously to PLA2s in Elapids, such 
as necrosis and inflammation could be (also) caused by the SVMPs.  
 
1.2.3.4 Neutralization of the systemic inflammatory response by current 
treatment 	  	  
Antivenom was proved to be efficient against the main threatening systemic effects 
resulting from envenomation (e.g. coagulopathy) (see part 1.1.6.2). Nevertheless, the use of 
antivenom seems to be partly inefficient against local manifestation induced by the 
inflammatory response to snake envenomation. 
 
Numerous studies were conducted on Bothrops jaraca (Viperidae family). In a first 
study, the neutralization of lethal and hemorrhagic effects of Bothrops jaraca venom was more 
effective than the neutralization of myonecrosis and edema. Antivenom was not effective on 
the oedema formation, whatever time or route of antivenom administration (J. M. Gutiérrez 
1981). In two another studies, antivenom was shown to reduce oedema and pain only if 
antivenom was injected in the very early stages: 15 minutes after venom administration (Picolo 
et al. 2002) or only if given in the first 30 minutes after venom injection (Araújo et al. 2007).. 
The myonecrotic effects were observed to be partially neutralized by antivenom; this only in 
the case where antivenom was administrated rapidly after venom injection (Chaves, Barboza, 
Gutiérrez 1995). The authors suggested that the lack of antivenom effectiveness on local 
manifestations of inflammation is based on the extremely fast manifestation of oedema and 
hyperalgesia after venom injection and their association with the release of endogenous 
mediators. Moreover, it is also thought that locally, the amount of antibodies is insufficient and 
delayed. Therefore, the time interval between snakebite and antivenom administration as well 
as the route of serum administration should be very important. However, the time between the 
snakebite and the animal’s presentation is unpredictable and is often over an hour in 
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veterinarian medicine (J. M. Gutiérrez 1981; Picolo et al. 2002). No specific study was 
conducted on the neutralization of the inflammatory response thanks to tiger snake antivenom. 
 
Looking at the lack of antivenom effectiveness against the management of clinical signs 
due to inflammatory response to envenomation, some studies suggest complementing this 
antivenom treatment. According to their observation on mice, indomethacin (non-steroidal anti-
inflammatory, acting as a cyclooxygenase inhibitor) and prazosin (α-adrenergic blocker) and 
dexamethasone (inhibitor of phospholipase A) were able to reduce the formation of oedema 
induced by B. asper venom (Chaves, Barboza, and Gutiérrez 1995). More recently, another 
study demonstrates that neither antivenom nor anti-inflammatory drugs (dexamethasone or, 
indomethacin) become effective if they are administered alone 45 minutes after Bothrops asper 
venom administration. Nevertheless, the association of dexamethasone and antivenom or 
indomethacin and antivenom appears to reduce significantly paw oedema when injected 45 
minutes after venom induction (Araújo et al. 2007). The inflammatory response seems to be 
characterized by the release of endogenous mediators, induced by some venom components, 
and also by the participation of metabolites and arachidonic acid. Therefore according to these 
findings, the association of anti-inflammatory drugs, such as dexamethasone or indomethacin, 
with antivenom could be a rational alternative to treat the local reaction induced by venoms. So 
far, no study in this area was conducted on tiger snake envenomation. 
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3. PART 2. EXPERIMENTAL PROTOCOL, RESULTS AND 
DISCUSSION 	  
3.1.  OBJECTIVES AND HYPOTHESIS 
 
Despite the severity of the condition, the mechanism and characteristics of the post-
envenomation syndrome that follows after the initial obvious crisis have only been 
insufficiently studied in dogs. Based on the known effects of components of Australian snake 
venom, it is likely that a marked systemic inflammatory response evolves in snake bitten dogs. 
If this is indeed the case, new therapeutic avenues open up to optimize post-envenomation care 
in dogs.  
We proposed a pilot study in order to determine the systemic inflammatory response in 
tiger snake envenomation and antivenom administration in dogs, through the evaluation of 
plasma IL-6 levels. The study measured whether there is evidence of inflammation occurring 
due to the snake venom and the antivenom administered. It was thought to improve treatment 
options for snake envenomed dogs in the future by providing novel information on the potential 
utility of anti-inflammatory treatment in dogs with snake bite in the future. 
 
We have hypothesized that a plasma marker of inflammation, the IL-6, was altered at 
presentation compared to a control group of healthy animals, and further increased after 
antivenom administration. 
The aim of this project is to determine to which extent tiger snake envenomation in dogs 
needs to be considered as a condition of systemic inflammation and whether clinical trials 
including non-steroidal or steroidal anti-inflammatory drugs are warranted. 
 
3.2. MATERIAL AND METHODS 
 
3.2.1. POPULATION: INCLUSION CRITERIA 
 
Naturally snake envenomed dogs (n=10) enrolled in this prospective observational study 
were followed from the initial presentation to the emergency service of the University of 
Melbourne Veterinary Hospital (UMVH) until hospital discharge or death. Healthy dogs (n= 4) 
have been included in this study as control group. The study protocol was approved by the 
University of Melbourne Animal Ethics Committee (AEC) prior to any research being 
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conducted and informed consent was obtained from the owners of all dogs enrolled in the 
study. 
Dogs were enrolled if they weight more than 5 kg, had a haematocrit > 30% at admission, 
had not receive any antivenom prior to admission or experience a prior snake envenomation 
within the preceding four weeks. Enrolment occurred based on the association of several 
factors: history of the dog, clinical evidence of snake envenomation, including combination of 
general symptom, haematological, myotoxicity and neurological signs. Diagnosis of tiger snake 
envenomation was considered to be reliable if tiger snake was witnessed and identified by scale 
counting or if the snake venom detection kit (SVDK) revealed tiger snake immunotype. 
 
3.2.2. GENERAL DATA 
 
General data were recorded following a questionnaire obtained via client interview and 
physical exam findings collected at the time of admission.  
 
Confounding variables 
Confounding data were collected if known or suspected to influence the clinical 
presentation and the inflammatory response. They include historical information with 
concomitant disease and current medical treatment, date and location of snakebite, 
environmental temperature of snakebite, time from snakebite to presentation, the number of 
antivenom vials administrated, and drugs administrated. 
 
Clinical variables 
In order to assess severity of illness of the dogs, clinical variables present prior to 
admission (e.g. vomiting, weakness or collapse) and at hospital admission (e.g. clinical signs of 
vomiting, weakness or collapse, muscle tremors, ataxia, dilated pupils, absent pupillary light 
reflex, respiratory arrest) were obtained. Heart rate, respiratory rate, Sp02, rectal temperature 
and systolic blood pressure assessed by oscillatory or Doppler method were also measured. 
 
Clinical outcome 
Clinical outcome was determined as survival to hospital discharge, duration of 
hospitalization, mode of death and in the case of euthanasia, as to whether this was primarily 
due to financial constraints or due to futility. 
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3.2.3. CLINICOPATHOLOGICAL DATA 
 
At the time of presentation, blood was collected from a cephalic, saphenous or jugular 
vein, placed in an EDTA and Heparin tube. Clinicopathological variables including 
biochemistry, electrolyte analysis, venous blood gas and coagulation time were assessed 
according to the choice of the clinician responsible for the animal. 
 
3.2.4. INFLAMMATORY MARKERS MEASUREMENTS: IL-6 LEVELS 
 
Whole blood samples (2 mL) were collected in sodium citrate tubes at presentation of the 
animal to the emergency service (i.e., prior to antivenom administration) (T0), within the two 
first hours after antivenom administration (T1), 18 hours (T18), and 24 hours (T24) after 
admission.  Only one sample was taken from the control cases. Samples were centrifuged with 
a speed of 3800Rpm (3200G)1, under 5°C for 5 minutes. Then, the supernatant plasma was 
immediately placed in polypropylene microtainer tubes and stored at -80°C until analysis for a 
maximum period of 6 months, without any freeze-thaw cycle. After collection, samples were 
frozen in a maximum delay of 3 hours.  
In the literature, EDTA tubes are recommended since chelating agents avoid any potential 
cytokine production after sampling. Heparin should be avoided as it is often contaminated by 
endotoxins, which strongly induce cytokine synthesis. Plasma or serum has to be decanted very 
rapidly to prevent any cytokine degradation or adsorption. Samples are recommended to be 
stored frozen (–80°C). The thawing-freezing cycles should be avoided, even though three 
cycles seem to have no influence on IL-6 determination (Bienvenu et al. 2000). 
 
The prototypical inflammatory mediator IL-6 was determined by using a quantikine 
ELISA kit standard2, validated to determine relative mass values for naturally occurring canine 
IL-6. Samples were brought to the temperature room before use. 50 µL of assay diluent were 
added to each well. 100 µL of Standard dilution (=10ng of recombinant canine IL-6), control or 
sample were then added. Plate was covered and incubated at room temperature for 2 hours on 
an orbital microplate shaker. Each well was aspirated and plate washed 5 times. Then, 200 µL 
of Conjugate solution were added to each well. Plate was covered with a new plate sealer and 
incubated at room temperature for 2h on the shaker. Each well was aspirated again and plate 
washed 5 times. 120 µL of substrate solution were added to each well and plate was incubated 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  Allegra	  6R	  Refrigerated	  Benchtop	  Centrifuge,	  Beckman	  Coulter,	  USA	  2	  Quantikine	  ®	  ELISA,	  Canine	  IL-­‐6,	  R&D	  system,	  USA	  &Canada	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at room temperature on the benchtop for 30 minutes (avoiding light).  Finally, 120 µL of Stop 
solution were added to each well. The absorbance of each well was read at 450nm within 30 
min (by a microplate reader).   
The detection level of IL-6 (sensitivity of the assay) was considered to be 11.8pg/mL, 
according to R&Dsystem (canine IL-6 Quantikine ELISA kit). 
 
3.2.5. STATISTICS 
 
A mann-Whitney test was realized to compare IL-6 levels to control cases for each time. 
A wilcoxon matched-pairs test was realized in order to compare IL-6 levels differences 
between each time.  The level of significance was considered to be p<0,05. 
 
3.3. RESULTS 
 
3.3.1. DOGS AND SNAKEBITE INFORMATION 
 
The study included 10 dogs (tabl.IX). There was no significant difference between 
females and males. Their average age was 4.4 years-old. Only pure breeds were presented. 
Their average weight was 19.6Kg.  One dog (case n°6) had a concomitant disease (skin 
allergy), currently treated with Atopica (cyclosporine). Another dog (case n°2) had incoagulant 
rat bait ingestion 12 months prior. And a last dog (case n°9) had a previous history of snake 
envenomation 4 months before. 
Snakebite was seen in 7 cases out of 10 (70%) without any scale counting determined.  
All snake envenomation occurred in West Melbourne. The time of admission ranged 
from 12:00 pm to 10:15 pm. The average local temperature was 26.7°C (with a minimum of 
21.1°C and a maximum of 31.7°C).  
The time spent between snakebite to admission was determined in 7 cases out of 10 and 
varied from 30 minutes to 80 minutes. First samples (T0) were collected at the admission (after 
clinical examination). Samples, collected after antivenom administration (T1), were taken on 
average 86 minutes after administration, ranging from 15 to 165 minutes. Samples collected at 
T18 and T24 were collected 18h and 24h after admission. The delay between snakebite and 
sample collection at T1 was on average 167 minutes (ranging from 110 to 206 minutes).  
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Table IX. Signalment and history 
Cas n° 1 2 3 4 5 6 7 8 9 10 
Age (year, month) 5y6m 4y 2y4m 1y6m 3y 10y10m 2y 7y 5y3m 5y3m 
Gender MN MI F F M FS FS F FS MN 
Breed CKC GSP Am. 
Staff. 
Dach
s. 
JRT CKC Schn. 
m. 
Akita Am. 
Staff. 
Border 
Collie 
Time from snake 
bite to admission 
(h) 
01:20 U U U 00:30 00:40 01:00 00:34 01:00 0 :45 
Age, gender, breed and time from snakebite to admission for each dog included in the 
study.  
 MN=Male Neutered, MI=Male Intact, F=Female Intact, FS=Female Spayed, 
U=Unknown, CKC=Cavalier King Charles, GSP=German shorthaired pointer, Am. 
Staff.=American Staffordshire Bullterrier, Dachs.=Dachshund, JRT=Jack Russel Terrier, 
Schn. m.= Schnauzer miniature 
	  
	  
3.3.2. CLINICAL FINDINGS 
 
All dogs were reported to present clinical signs before admission. The most common 
clinical signs prior admission were collapse (on 5 out of 10 dogs) and vomiting (on 3 out of 10 
dogs), followed by weakness and hypersalivation (2 dogs) and diarrhea (1 dog). 
At the initial examination, abnormal findings included vomiting and collapse (3 dogs), 
hypersalivation (2 dogs), nausea (1 dog), muscle tremors (1 dog). Mydriasis and loss of 
pupillary light reflexes were observed in three dogs. Mentation was altered in one dog, which 
was hyperexcited. One dog presented ataxia for a few hours.  
 
 
Diagram 3. Clinical signs present at the admission (on 10 dogs) 
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Only one dog (case n°1) presented tachycardia (with a HR=160bpm). Tachypnea was 
reported in four dogs (BR>40mpm). Two dogs presented hyperthermia (39.2°C and 39.4°C). 
Systolic blood pressure was determined by either Oscillometry or Doppler on five dogs, and 
was considered as normal (between 110 and 131 mmHg). 
 
3.3.3. BICHEMISTRY, HAEMATOLOGY AND CELL BLOOD COUNT, 
COAGULATION TIMES 
 
The time spent between the bite to the admission was known in 7 cases out of 10 and was 
on average 55 minutes (between 30 and 80 minutes). First blood samples were taken 
immediately after admission (T0), depending on clinician's decision.  
Serum biochemistry3 was performed on nine dogs (Tabl.X). CK was determined for 8 out 
of 10 dogs and was increased for 7 out of these 8 dogs (from 379 to 25,571mmol/L). Total 
proteins were increased in 2 ou of 10 dogs. ALKP were measured for three dogs and severely 
increased in one dog (case n°6). Bilirubinemia was slightly increased in one dog. Electrolyte 
analysis was performed on six dogs (Tabl.XI) and showed moderate to slight hypokaliema in 3 
out of 6 dogs.  
Table X. Laboratory diagnosis: biochemistry 
 
 Biochemistry results at the admission for each dog included in the study. Main 
abnormalities are increased CK (7 out of 8 dogs), increased hepatic parameters (3 out of 6). 
ALT=aminotransferase, ALKP=alkaline phosphatase. No data for case n°8. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  IDEXX	  catalyst	  DX	  Chemistry	  Analyzer,	  Australia	  
 Ref Case 
n°1 
Case 
n°2 
Case 
n°3 
Case 
n°4 
Case 
n°5 
Case 
n°6 
Case 
n°7 
Case 
n°9 
Case 
n°10 
Total protein 
[g/dL] 
52-82 60 60 70 71 84 60 66 50 92 
Albumin 
[g/dL] 
23-40  45    40  67 33 
Glucose 
[mmol/L] 
4.11-
7.95 
6.00 4.53 7.90  9.90 6.2 5.8  5.75 
Creatinine 
[mcmol/L] 
44-
159 
 105    74   89 
Urea 
[mmol/L] 
2.5-
9.6 
 5,8    3   7.5 
ALKP [U/L] 
23-
212 
 25    1993   163 
ALT [U/L] 10-
125 
 226    78   138 
Bilirubin 
[mcmol/L] 
0-15   2   2  18  
CK <100 13,319 1,583  25,571 1,362 379 1,021 <100 19,940 
	   81	  
Table XI. Laboratory diagnosis: electrolytes 
 Ref Case 
n°1 
Case 
n°2 
Case 
n°3 
Case 
n°6 
Case 
n°7 
Case 
n°9 
Na [mmol/L] 145-158 146 145 146 146 142 144 
K [mmol/L] 3.6-5.8 3.6 2.9 3.2 3.5 3.9 4.4 
Cl [mmol/L] 105-122 113 119 120 121 117 115 
Electrolyte analysis results for six dogs at the admission Moderate to slight kypokaliema 
in 3 dogs. No data for cases n°4, 5, 8 and 10. 
 
Blood cell counts4  included only haematocrit and platelets (PLT) were determined 
respectively on nine and eight dogs respectively (Tabl.XII). Haematocrit was increased on 7 
out of 9 dogs. 1 out of 8 dogs had thrombocytosis and 4 out of 8 dogs had thrombocytopenia. 
Serum was haemolysed on 9 out of the 10 dogs. 
 
Table XII. Laboratory diagnosis: cell counts 
	   Ref	  
Case	  
n°1	  
Case	  
n°2	  
Case	  
n°3	  
Case	  
n°4	  
Case	  
n°5	  
Case	  
n°6	  
Case	  
n°7	  
Case	  
n°9	  
Case	  
n°10	  
Haematocrit	  
[%]	  
33.6-­‐
47.4	   44	   52	   52	   47	   62	   49	   58	   56	   92	  
Platelets	  
[x10^3/mcL]	  
200-­‐
500	   203	   244	   183	   556	   180	   158	   156	   	   254	  
Haematocrit	  and	  platelets	  results	  at	  the	  admission	  for	  each	  dog	  included	  in	  the	  study.	  
Increased	   haematocrit	   (7	   out	   of	   10	   dogs)	   and	   both	   thrombocytopenia	   (4	   out	   of	   8	   cases),	  
thrombocytosis	  (1	  out	  of	  8	  cases)	  are	  noticed.	  No	  data	  for	  case	  n°8.	  
 
Acid base status and lactate5 were assessed on six dogs (Tabl. XIII): hyperlactatemia was 
present on 5 out of these 6 dogs. Systolic blood pressure was in the reference range for all dogs 
tested. 
Table XIII. Laboratory diagnosis: acid base status 
	   Ref	  
Case	  
n°1	  
Case	  
n°2	  
Case	  
n°3	  
Case	  
n°5	  
Case	  
n°6	  
Case	  
n°7	  
Case	  
n°9	  
pH	   7.350-­‐7.440	   7.319	   7.257	   7.401	   	   7.393	   7.195	   7.408	  
HCO3	  [mmol/L]	   22-­‐22	   21,5	   	   19,3	   	   21,7	   16,2	   	  
PvCO2	  [mm	  Hg]	   33.0	  -­‐	  52	   43.1	   41.8	   31.7	   35	   36.4	   32	   34.3	  
Lactate	  
[mmol/L]	   0.6	  -­‐	  2.5	   3	   4.4	   2.8	   3.4	   1.4	   9.1	   	  
Acid	  base	  status	  results	  at	  the	  admission	  for	  each	  dog	  included	  in	  the	  study.	  A	  slight	  
acidosis	  is	  noted.	  No	  data	  for	  cases	  n°4,	  8	  and	  10.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  4	  IDEXX	  Procyte	  Dx	  Hematology	  Analyzer,	  Australia	  5	  Radiometer	  ABLFlex800	  Analyser,	  country,	  year	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Prothrombin (PT) and activated partial thromboplastin times (aPTT)6 were collected in 
EDTA and were at least increased for 9 of the 10 dogs (Tabl. XIV). 
	  
 
3.3.4. DIAGNOSIS OF SNAKE ENVENOMATION 
 
Snakes were witnessed for all dogs. A picture was taken for one of the snakes and 
clinicians confirmed diagnosis. Snake venom detection kits (SVDK)7 were performed on 2 out 
of 9 dogs using urine and serum. Results revealed in both cases tiger snake immunotype (Tabl. 
XIV). 
 
Table XIV. Major criteria for laboratory diagnosis of envenomation 
 Case 
n°1 
Case 
n°2 
Case 
n°3 
Case 
n°4 
Case 
n°5 
Case n°6 Case 
n°7 
Case 
n°8 
Case 
n°9 
Case 
n°10 
PT 
(14-19s) 
NA NA 10 44 10 NA NA NA NA NA 
aPTT  
(100-
120s) 
>300 >300 103 >300 >300 163 >300 >300 >300 >300 
Colour 
of 
serum 
Haem. Haem. Haem
. 
Haem. Haem. Normal Hae
m. 
Haem.  Haem. Haem 
CK <100 13,319 1,583  25,571 1,362 379 1,021 <100 19,940 
SVDK Yes U No Yes S No No No No No No No 
SVDK 
results 
Tiger  Tiger         
2nd 
SVDK 
Yes W Yes U No No No Yes W No No Yes W Yes U 
SVDK 
results 
Neg Neg    Neg   Neg Neg 
 
Coagulation times, color of serum, CK, SVDK test at admission and sample used for it 
and potential second SVDK test were recorded in order to make a diagnosis of envenomation. 
Increased PT (8/10), aPTT (9/10), haemolized serum (9/10), increased CK (7/9), positive 
SVDK (2/2) were considered in favor of snake envenomation. 
PT=Prothrombin time, aPTT=activated Partial Thromboplastin Time, CK=Creatin Kinase, 
SVDK=Snake Venom Detection Kit, U=Urine sample, S=Serum sample, W=Whole blood 
sample, 2nd SVDK=SVDK repeated after antivenom administration, NA=Non Applicable, 
Haem. =Haemolized  
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  6 IDEXX Coag Dx Analyser 7 Snake Venom Detection Kit, CSL Limited, VIC, Australia	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3.3.5. KINETIC FOLLOW-UP OF IL-6 
 
IL-6 was quantified at each time following envenomation (T0, T1, T18, T24) except for 
two dogs (case n°3 and case n°5) in which IL-6 was measured at only T0 and T18 (due to some 
reasons such as the lack of serum for analysis, owner’s decision to take the dog home or 
material availability).  
The serum concentration ranges from 0pg/mL to 260pg/mL with an average of 33pg/mL 
(Graph. 1). IL-6 was indictable for all control cases. The average IL-6 concentration was above 
the detection level at each time and IL-6 was significantly more increased at T1 during the first 
two hours after antivenom injection compared to the control case (mean=89.9pg/mL, ranging 
from 4.7 to 260.0pg/mL, p-value=0.004 for difference between control and affected dogs by 
Mann-Whitney test) (Graph. 2). There were no significant differences between IL-6 levels at 
T0, T18 and T24 compared to control cases (p>0.05, by Mann-Whitney test). Moreover, IL-6 
levels were significantly higher at T1 compared to IL-6 levels at T0 and at the other times (p-
values < 0.005 for difference between levels at T1 and each other times T0, T18 an T24, 
Wilcocxon matched-paired signed rank test). There were no significant differences comparing 
IL-6 levels at T0, T18, T24 (p-values>0.9, Wilcocxon matched-paired signed rank test). 
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Graphic 1. Mean, median and quartile of IL-6 levels for each time in affected and 
healthy dogs 
 
 
 
 
 
IL-6 serum concentration was determined at the admission (T0), in the first two hours 
after the admission (T1), 18 hours after the admission (T18) and 24 hours after the admission 
(T24). IL-6 levels ranged from 0pg/mL to 260pg/mL. IL-6 was indictable for all control cases. 
No data for two dogs at T1 and T24.  
Tall bar=mean, small bar=standard error of mean (SEM) 
*p-value is Mann-Whitney Test comparing healthy controls and affected dogs 	    
*p	  value	  =	  0.054	   *p	  value	  =	  0.004	  
*p	  value	  =	  0.296	   *p	  value	  =	  0.208	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Graphic 2. Evolution of mean IL-6 levels depending on time post admisison 
 
Evolution of mean IL-6 levels after admission at the hospital. The mean IL-6 
concentration is above the detection level at each time and IL-6 is significantly increased at T1 
(b*), after antivenom injection, compared to T0 and to the other times (Wilcoxon matched 
paired test). Bar=standard error of mean (SEM). 
 
Three dogs showed significantly increased IL-6, at at least two times, especially at T1 
(cases n°4, 7 and 10). Three dogs (cases n°1, 3 and 9) showed IL-6 levels below detection level 
for all times (including the dog n°3 for which data was only obtained at T0 and T18). Two dogs 
(cases n°2 and n°6) had IL-6 levels above detection level only at T1 and one dog (case n°5) had 
IL-6 levels above detection level only at T18 (data unknown at T1 and T24). A last dog (case 
n°8) had IL-6 levels slightly increased (33.8pg/mL on average) and stable at all times (Graph. 
3).	   Graphic	  3.	  Evolution	  of	  IL-­‐6	  levels	  for	  each	  dog 
 
 Evolution of IL-6 levels measured at the admission, after antivenom administration, 18 
hours and 24 hours after admission for each dog. 
a	   	  	  	  a	   	  a	  
	  	  	  b*	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3.3.6. TREATMENT AND OUTCOME 
 
Six dogs out of ten received 1 vial (3,000-4,000 units) and four dogs received 2 vials 
(6,000-8,000units) of the antivenom. A bivalent tiger snake / brown snake antivenom was used 
in the majority of dogs (8 out of 10 dogs) and a monovalent antivenom was administrated in 
two dogs in which SVDK revealed tiger snake immunotype. All dogs received fluid therapy 
(Lactated Ringer’s solution at 2.5mg/Kg/h) and analgesia (Buprenorphine at 0.02mg/Kg IV or 
Methadone at 0.1mg/Kg depending on the dog’s comfort).  
Results of SVDK were used to guide repeated administration of antivenom for 5 dogs out 
of 9 and all results were negative. Therefore, no further antivenom administration was made. 
Hypersensitivity was noted for one dog (case n°1) and was characterized by facial puritis 
and erythema affecting skin around mouth and chin. An antihistaminic (Chlorpheniramin) was 
given and the antivenom administration was stopped. No further signs were noticed. One day 
after admission, one dog (case n°10) presented a progressive and rapid decrease in haematocrit 
(until 13%) and was suspected of mediated immune hemolytic anaemia. He received a red 
blood cell transfusion on day 2 of its hospitalization. 
All dogs were discharged alive. No mechanical ventilation was required. The median 
duration of hospitalization was 1.7 days (ranging from 1 to 5 days). The cost on discharge was 
on average 980 AUS dollars.  
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3.4. Discussion 
 
In this study, a marker for systemic inflammation, Interleukin-6 and also clinical and 
clinicopathological parameters were investigated.  
 
3.4.1. THE INFLAMMATORY RESPONSE 
 
Snake envenomation was described as a complex inflammatory reaction in which 
cytokines and acute phase proteins play a major role. In a study on Bothrop asper 
envenomation, IL-6 was thought to be involved in leucocyte influx neutrophil activation and 
maturation as well as in the stimulation of molecules’ adhesion on endothelial cells to form a 
cellular infiltrate (Stella R. Zamuner et al. 2005). 
 
Evidence of inflammatory systemic response 
IL-6 levels were above the detection level for 4 out of 10 dogs at T0, for 6 out of 8 dogs 
at T1, for 3 out of 10 dogs and 3 out of 8 dogs at T18 and T24. Unlike our hypothesis, plasma 
markers of inflammation were not significantly altered at dogs’ presentation (T0) but only at T1 
– during the two first hours following antivenom administration. In clinically healthy dogs, the 
serum concentration was never above 0pg/mL. There were some big variations between 
animals for IL-6 values, indicating different effects following inflammation of affected 
animals. Unfortunately, there is no study in which a reference interval for IL-6 in dogs has been 
calculated. However, similar values and disparity of IL-6 levels in dogs studies with healthy 
controls were reported. For example, IL-6 concentration in dogs with hepatitis and hepatic 
tumours were between 1 to 20 pg/mL (Neumann, Kaup, and Scheulen 2010). Dogs with local 
inflammation induced by intramuscular injection of turpentine oil had increased IL-6 levels 
ranging from 0 to 204.4 pg/mL (Yamashita et al. 1994). In our study, the IL-6’s mean 
concentration for dogs envenomed by snakes is comparable to the one of dogs with primary 
hepatic tumour (Neumann, Kaup, and Scheulen 2010). Given the very low reference value, any 
increase of IL-6 can be easily recognized. Thus, in the present study, even if IL-6 was 
significantly increased at T1 only, there is still evidence of systemic inflammatory response for 
numerous dogs at all collection times.  
 
IL-6 levels, clininical and clinicopathological correlation 
Clinically, among the dogs with very high IL-6 levels, one dog presented only vomiting 
at the admission, another dog had weakness and hypersalivation and the last one had collapsed 
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before admission. Nevertheless, these signs were also observed on dogs with the lowest IL-6 
levels. On the three dogs with the highest IL-6 levels, one had increased CK (19.940 mmol/L), 
one had CK within the reference (379 mmol/L) and CK was not measured for the third one due 
to financial reasons. High CK levels were also observed for dogs without any increase in IL-6 
levels. Moreover, the lack of haematological and biochemical tests for some dogs make any 
biological correlation difficult. Haemolized plasma was observed on both, dogs with high IL-6 
levels and dogs with low IL-6 levels. Since the collected samples for biochemical and 
haematological analysis were taken generally at the admission, it could have been interesting to 
analyze these parameters at each time in order to follow their evolutions. The longest 
hospitalization concerned a dog with a high IL-6 level but the duration remained quite similar 
than the one for other dogs, no further correlation could be made. Thus, no clinical or 
biological correlation could be made with the animals that had the highest levels of IL-6. 
 
IL-6 levels and antivenom administration 
In our study, the inflammatory response is more important at T1, after antivenom 
administration. Indeed, at T1, a higher number of dogs have their IL-6 level more severely 
affected by an increase compared to T0. Nevertheless, the delay between antivenom 
administration and snakebite was (if known) quite similar between dogs with or without high 
IL-6 levels. Thus, no correlation could be made with delayed antivenom administration. The 
number of vials administrated varied from one to two, and more antivenom was given to dogs 
with either high and low IL-6 levels. No correlation could be made between delayed antivenom 
administration or antivenom posology and IL-6 levels. 
 
Antivenom administration, current standard treatment, was found to further exacerbate 
the venom induced inflammatory up-regulation and constitute a second pro-inflammatory hit 
(León et al., 2011, Stone et al., 2013). Indeed, two kinds of reactions induced by antivenom 
administration have been described: early reactions and late reactions. Late reactions 
correspond to a syndrome called “serum sickness” - it can appear 5 to 20 days after treatment 
and do not concern our study. Early reactions occur during the first hours following antivenom 
administration and the pathogenic mechanisms involved include pyrogenic and anaphylactic 
reactions with Ig-E and non Ig-E mediated reactions. Pyrogenic reactions are mainly 
characterized by hyperthermia, myalgia, nausea, sweating, tachycardia, and vasodilation with a 
secondary fall in blood pressure. They mainly imply bacterial lipopolysaccharides (LPS) in 
biologically-derived pharmaceuticals, stimulating monocytes and macrophages to produce 
cytokines such as IL-1, IL-6, INF-γ and TNF-	  α (León et al., 2011, Stone et al., 2013) and thus 
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could explain any rise in IL-6 levels. In the study of Stone et al., they noticed that patients 
presented astonishing levels of immune activation after antivenom administration. This 
immune activation was observed whether a reaction occured or not. Nevertheless, increases in 
inflammatory mediator levels (IL-6, IL-10, TNF-α) were highest in patients who also had 
pyrogenic reactions. Nevertheless, in our study, the dogs with the most altered IL-6 at T1 (dogs 
n°4, n°7 and n°10), showed none or slight signs of pyrogenic reaction (no hyperthermia and no 
hypotension for all dogs / only tachycardia at 152bpm and 150bpm for two dogs). Thus, in our 
study, pyrogenic reactions did not seem to be related to the inflammatory response noticed. As 
antivenom is formulated from hyperimmune IgG serum (CSL antivenom, 2014), it is possible 
that antibodies to antivenom participate to the induction of the inflammatory response. Stone et 
al. have suggested that antivenoms contain aggregates of immunoglobulins that have the ability 
to crosslink IgE receptors on the surface of mast cells resulting in non-allergen specific mast 
cell degranulation. In that study, they also noted an increase in IL-6 levels even when no 
hypersensitivity reaction to antivenom occurred. One dog in our study showed facial pruritus 
consistent with a hypersensitivity reaction, but IL-6 level was below the detection limit of the 
assay for each time (4,7pg/mL at T1). Considering the massive increase in IL-6 levels after 
antivenom administration, even if no pyrogenic or anaphylactic reaction have been noted, an 
immune response to antivenom, in addition with the inflammatory response induced by the 
venom itself, could not be excluded.  
 
IL-6 levels and time effect  
IL-6 levels were elevated at the early stages of envenomation, starting at the admission - 
T0 which was estimated in average to be 55 minutes after snakebite  (4 out of 10 dogs). On the 
other hand, less dogs had increased IL-6 levels at T18 (3 out of 10 dogs) and T24 (3 out of 8 
dogs) and increases were not significant. This early induction in IL-6 release was also found 
between 1 and 3 to 6 hours, peaking 3 hours after intraperitoneal injection of Asper bothrop 
venom in mice, returning to normal after 12 hours (Moreira et al. 2012). Nevertheless, in the 
present study, IL-6 was still above the reference value 18 hours and 24 hours after admission 
for 3 out of 10 dogs.  
These results are also consistent with previous works in humans envenomed by snakes 
who showed elevated concentrations of IL-6, IL-8 and TNF-α. The inflammatory response in 
children following a Bothrops snake envenomation was studied by Ávila-Agüero et al. (2001) 
and showed an increase of IL-6 and IL-8 during the first 12-24 hours. Cytokine concentrations 
were detectable prior to antivenom administration and returned to normal 72 hours later. In 
another study of humans envenomed by Sri Lankan snakes (Stone et al. 2013), plasma 
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concentrations of IL-6, IL-10, C4a and C5a were significantly higher in envenomed patients 
before they received antivenom and IL-6 concentration increased rapidly and significantly after 
antivenom administration. These higher values after antivenom administration, also detected in 
our study can lead to question if there is an influence of antivenom administration on the 
inflammatory response as seen previously, or whether this is just a time effect between 
antivenom administration and the time required to elaborate IL-6 and to release it in the 
circulation. In a study on the kinetic of IL-6 changes, in which dogs received an intraveinous 
bolus of high dose lipopolysaccharide solution to induce sepsis, IL-6 levels increased at 1 hour, 
peaked at 3 hours and remained high until 24 hours (Song et al. 2012). In our study, the delay 
between snakebite and sample collection at T1 was on average 167 minutes (ranging from 110 
to 206 minutes).  The delay between antivenom administration and sample collection at T1 was 
on average 86 minutes (ranging from 15 to 165 minutes). Thus, the release of IL-6 in the 
circulation could match with the time required for the elaboration of the inflammatory response 
to the envenomation. Moreover, a bias exists in our study due to the lack of data (i.e. snakebites 
unknown for three dogs, including one of the dogs with highest IL-6 levels) and the fact that 
there is a wide disparity of delays between antivenom administration and sample collection at 
T1 due to some management reasons at the ICU (e.g. personnel avaibility, animals priority, 
samples collected at the same time for both the experiment and blood analysis as required by 
the clinician in order to minimize the number of venipunctures). 
 Among the three dogs for which IL-6 reached the highest levels at T1, one dog (dog n°4) 
had no determined time of snakebite. For another dog (dog n°7), blood was collected at T1 15 
minutes after antivenom administration, corresponding to 130 minutes after snakebite; thus, in 
this case, elevation of IL-6 seemed pretty quick to be explained by the antivenom and thus 
would probably be due to the envenomation itself.  For the last dog (dog n°10), the delay was 
120 minutes between antivenom administration and blood collection at T1 and 165 minutes 
between snakebite and blood collection at T1. Thus, no conclusion could be made (delay was 
considered to be too similar). In this way, no correlation could be clearly made between the 
time required by the organism to elaborate IL-6 and the antivenom administration time or the 
envenomation time itself. 
 
Adjuvant treatment 
The previous considerations could lead to the perspective of new therapeutic objectives in 
conjunction with antivenom therapy regarding tiger snake envenomation. Since, on one hand, 
only one dog showed a reaction to antivenom administration of poor severity (pruritus) in our 
study, and, on the other hand, the literature (Armentano and Schaer 2011) showed  low 
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prevalence of reactions for dogs, antihistamine drugs do not appear to be systematically 
necessary in tiger snake envenomation.   
 
The use of corticosteroids and nonsteroidal anti-inflammatory drugs (NAIDs) is very 
controversial. Secondary effects (nephropathy and gastrointestinal ulceration) associated with 
NAIDs can be a fatal complication in envenomed patients and no in-vivo prospective canine 
studies have been performed to justify its use at this time (Armentano and Schaer 2011). Most 
of the current literature does not recommend the use of glucocorticoids. Moreover, a lot of 
these studies are retrospective studies and study design limitations have been raised. For 
example, a retrospective study on 327 dogs envenomed by Vipera palaestinae showed higher 
mortality with glucocorticoid therapy. But the authors also added that clinicians tend to give 
glucocorticoids therapy to more severely affected dogs first (Segev et al. 2004). The same 
limitation was found in a retrospective study on 53 Swedish dogs envenomed by Vipera berus, 
in which the group of dogs treated with glucocorticoids showed a trend towards a greater 
degree of swelling. But once more, the severity of clinical signs at presentation may have 
influenced the clinician to add glucocorticoids (Lervik, Lilliehöök, and Frendin 2010). A more 
recent prospective study, using randomly placebo in a clinical trial on dogs envenomed by 
Vipera berus, concludes that frequent use of glucocorticoids in dogs is not necessary since it 
did not significantly affect any clinical or clinicopathological parameters studied (Brandeker et 
al. 2015). Nevertheless, these studies looked at several snake species and none was conducted 
on tiger snake envenomation. No dog received any anti-inflammatory treatment in our study. 
 
However, there are also some literatures to support glucocorticoids use. Indeed, the 
participation of arachidonic acid and metabolites as well as the release of endogenous 
mediators induced by venom components can justify its use. The stimulation of the 
inflammatory response induced by PLA2 and SVMP, important component of snake venom, 
have been particularly studied in Bothrops asper (Farsky et al. 2000; Kanashiro et al., 2002; 
Zuliani et al. 2005). For mice, dexamethasone administration in conjunction with serum 
therapy were shown to be beneficial to treat inflammatory oedema caused by Bothrops 
jararaca (Araújo et al. 2007). Moreover, a wide variety of glucocorticoid drugs can be 
administered, from anti-inflammatory to immunosuppressive doses, and in multiple species, 
rendering a clinical interpretation of the limited research data very difficult (Armentano and 
Schaer 2011).  
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3.4.2. CLINICAL AND CLINICOPATHOLOGICAL FEATURES 
 
Clinical signs 
Dogs with mild envenomation were presented with non-specific clinical signs such as 
collapse and vomiting, which are common findings in dogs with envenomation. None of the 
dogs involved in the study had local signs of snakebite e.g. oedema, erythematous area, etc. 
According to an experimental study of 1994 in which tiger snake venom was injected in dogs 
with various dose rates, envenomation results primarily in neurological, myolitic anc 
coagulopathic clinical syndromes. Three categories of signs were defined as pre-paralytic, 
paralytic and lethal or delayed signs. Dogs envenomed by tiger snake presented collapse due to 
systemic hypotension, vomiting, salivation, defaecation and tachypnea in the pre-paralytic 
stage, skeletal muscle paralysis, coagulopathic signs, oliguria with or without haemoglobinuria 
or myoglobinuria in the paralytic stage and mydriasis, slow or absent pupillary reflex, stiff gait, 
ataxia, signs or renal failure in the sublethal stage (Lewis 1994; Heller et al. 2007). In our 
study, neurological signs included mainly mydriasis, which was also previously described to be 
the most common clinical sign - occuring in 76% of dogs with tiger snake envenomation (Barr 
1984). Other neurological signs such as hindleg ataxia and flaccid paralysis were also observed 
in respectively 35% and 41% of dogs, we did not observe those signs in our study. In the same 
study,  weakness and vomiting were frequent clinical signs following tiger snake envenomation 
(for respectively 37% and 53% of cases). In a study looking at clinical syndromes associated to 
humans envenomed by tiger snake, all envenomed patients developed Venom Induced 
Consumption Coagulopathy (VICC), neurotoxicity (53%) or myotoxicity (11%) alone or in 
combination. Systemic symptoms were the most common findings (80%) with nausea, 
vomiting and headache (44%, 35%, 34% respectively) (Geoffrey K. Isbister et al. 2012).  
Clinical signs observed after snake envenomation are variable depending on snake 
species involved, probably given the different toxins in their venoms. For example, altered 
mental status was not often observed in our study, unlike in the study of (Lervik, Lilliehöök, 
and Frendin 2010) in which 73% of dogs envenomed by Vipera berus had an affected mental 
status on arrival at the hospital. Diarrhea was also seen in one third of the dogs envenomed by 
this species (Brandeker et al. 2015). It is also the most common clinical sign in humans.  
However, gastrointestinal signs (e.g. diarrhea) are not frequently reported in dogs with tiger 
snake envenomation. 
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Alteration in biochemical and haematological parameters  
The most affected biochemical parameters were CK since almost all dogs presented 
moderate to severe CK levels increase. This is probably caused by muscle damages at the 
snakebite. Myotoxicity is defined as an elevated creatine kinase level associated with myalgia 
and/or muscle tenderness and is thought to be mainly due to notexin, one of the most important 
toxins of tiger snake venom. Notexin is a potent myotoxic and presynaptic PLA2 (Fry 1999), 
that induces a rapid local and generalised skeletal muscle myodegeneration, even after low 
doses of venom according to a study on histological examination of experimentally envenomed 
dogs tissues (Lewis 1994). Hyperlactataemia was present in several dogs and may be the result 
of an increased oxygen consommation by muscles. A slight lactic acidosis was noted in some 
dogs, without any abnormality of systolic blood pressure. The dog with increased ALKP 
received also cyclosporin for skin allergy, and thus no link with the envenomation was 
established. Except for significant CK level increases, the biochemical changes in our study 
were mild, as it was in other studies in which no significative alteration other than for CK were 
reported (Barr 1984; Geoffrey K. Isbister et al. 2012).  
Haemoconcentration, characterized by an increased in haematocrit, was observed in 7 out 
of 10 dogs in our study. It was also found in another study on an Elapid snake (Naja 
annulifera) (Lobetti and Joubert 2004). However, it was only rarely described in Elapids and 
more frequently reported in Viperidae envenomation (puff-adders and viper) (Segev et al. 
2004; Aroch et al. 2010; Lobetti and Joubert 2004). In these last studies, abnormality was 
explained by fluid losses and translocation of proteins and fluids from the circulation to the 
inflamated tissue at the bite site. Nevertheless, if there is evidence of local response to 
envenomation by these species, there is typically no local response observed in dogs with tiger 
snakebite. Splenic contraction may also be involved associated with excitement, pain, stress 
and subsequent release of stored erythrocytes into circulation (Goddard et al. 2011).  
We noticed that plasma serum was almost always hemolysed, which could suggest 
hemolysis. It is thought to be the consequence of lytic factor or phospholipase activity 
contained in tiger snake venom (Goddard et al. 2011). Moreover, almost all dogs presented 
signs of coagulopathy, as reflected by strong increase of PT and aPTT, a common finding in 
Elapid snake envenomation (Holloway and Parry 1989; Geoffrey K. Isbister et al. 2012; 
Geoffrey K. Isbister 2010). A slight thrombocytopenia was observed in 4 out of 10 dogs, which 
is usually more common in Viperidae envenomation (Goddard et al. 2011). Based on the 
current diagnostic criteria for DIC, including prolonged PT and aPTT, thrombocytopenia, 
increased concentration of D-dimers or fibrin degradation products (FDPs), and fibrinogen 
depletion, we observed some of the criteria compatible with potential disseminated 
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intravascular coagulation. Prolonged PT and aPTT may be the result of decreased prothrombin 
and fibrinogen concentrations and increased FDPs, which are probably the direct results of the 
venom procoagulant action, rather than the beginning of disseminated (or localised) 
intravascular coagulation. If venom is slowly absorbed from the envenomation site, its blood 
concentration will be low, and, fibrinogen will be consumed without intravascular fibrin 
deposition (or thrombus formation) (Holloway and Parry 1989). This consumptive 
coagulopathy associated with snakebites has been referred as a VICC (Venom Induced 
Consumption Coagulopathy) described in several different snake species envenomation 
including Elapids (Goddard et al. 2011). VICC is characterized by prolonged clotting times, 
depletion of fibrinogen and cofactors V and VIII, and high concentrations of FDPs, but does 
not include evidence of thrombus formation and organ failure. The VICC results from the 
activation of the coagulation pathway due to components of Elapid venoms, including 
procoagulants (such as prothrombin activators, FV and FX activators). The VICC also differs 
from rapid onset and resolution, which was observed in all our cases. The time from the bite to 
the complete defibrination can vary from 15 minutes to many hours and sometimes days for 
some species of Elapid. Spontaneous bleeding is rare following bites by these snakes but any 
vascular damages can cause major bleeding (White 2005). In our study, there was no 
correlation between haemostatic abnormality and severity of envenomation. All dogs were 
discharged alive. 
  
Concerning the treatment and the outcome, antivenom administrated was always the 
bilavent tiger snake and brown snake immunotype. On the retrospective study piloted at the 
Melbourne University Hospital from March 1973 to March 1983, both antivenoms (tiger and 
brown snake immunotypes) were administrated in Victoria if the snake could not be identified 
but they also precised that from their experience, tiger snake antivenom alone would cover 
nearly all envenomations from the Werribee area (Barr 1984).  
The number of vials administrated was correlated to clinical signs observed after the first 
antivenom administration and did not seem to be associated with the severity of clinical signs at 
the arrival at the hospital. A longer hospitalization was associated with CK level increase. 
Indeed, hospitalization was recommended as long as CK level did not decrease sufficiently 
from its highest concentration. No dog died during hospitalization and the disease evolution 
was benign with a mental status returning to normal in all dogs within the first day. 
Nevertheless, the outcome was biased by the fact that dogs envenomed more than 24 hours 
before admission were not enrolled. Indeed, when the time of the snakebite was known, the 
average delay between snakebite and antivenom administration was 83 minutes (ranging from 
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45 to 130 minutes), which is a quite short delay and we know that the shorter the delay between 
snakebite and antivenom administration the better the prognosis. Antivenom therapy is more 
effective if given as soon after the bite as possible. Previous works have shown that a delay in 
administration of antivenom is followed by delayed response or slow recovery (Barr 1984). 
Outcomes of our study are thought to be relatively good because admission occurred within the 
same day of envenomation and antivenom was administrated rapidly.  
 
3.4.3. LIMITATIONS 
 
This study has some limitations. The first limitation is the small number of dogs 
considered, which maked comparison and correlation very difficult. 
 
The SVDK was determined in only two cases and there were the only cases confirmed 
positive for tiger snake immunotype. This immunotype is shared by the tiger snake (Notechis 
scutatus), the common copperhead (Australeps superbus) and the rough scaled 
snake (Tropidechis carinatus) (White J, 2013). However, the tiger snake is the only species 
known to exist in the western suburbs of Melbourne (Mirtschin et al. 1998) where the 
University of Melbourne Veterinary Hospital is located. In one case, owners brought a picture 
of the snake, which was recognized to be a tiger snake by clinicians. Thus, diagnosis can be 
reasonably considered as reliable for these three cases. The SVDK could not be used in all 
cases due to financial request from the owner. Nevertheless, a combination of an appropriate 
history, clinical signs, laboratory tests, marked prolongation of coagulation times, an elevated 
CK and knowledge of experienced clinicians were considered to be sufficient for the diagnosis 
of snake envenomation.  
 
For this pilot study, biochemistry and haematology were only assessed depending on the 
clinician’s decision and owners’ one, therefore the lack of data for several dogs made an 
accurate interpretation difficult. Systematic and iterative biochemical and haematological tests 
could have been helpful in diagnosis as well as to better characterize the severity of the 
envenomation and to support evidence of an inflammatory response (e.g. anemia, leukocytosis, 
etc.).  
 
In the same perspective, there was a lack of data concerning the exact time of snakebite 
and thus the exact delay between snakebite, IL-6 measurement and antivenom administration. 
Unfortunately, as snake envenomations on dogs are not always observed by their owner, it is a 
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very difficult parameter to control. Moreover, time collection after antivenom administration 
was very difficult to control because depending on the avaibility of personnel in the ICU and on 
the clinician decision to collect blood for the animal’s health.  
 
Systemic and sometimes local effects induced by snake venom are characterized by an 
acute inflammatory response with accumulation of leukocytes and release of numerous 
mediators. Many authors, working on the inflammatory response induced by venom of 
Viperidae snakes, investigated the release of numerous cytokines, chemokines and/or other 
mediators such as IL-1, IL-6, IL-8, IL-10, TNF-	  α, CRP, Regulated on Activation Normal T 
cell Expressed and Secreted (RANTES) (Lomonte, Tarkowski, and Hanson 1993; Stone et al. 
2013; ÁVILA-AGÜERO et al. 2001; Zamuner et al. 2005). Nevertheless, due to financial and 
practical reasons, IL-6 was the only cytokine measured in this study. Thus, as these mediators 
have different biological activities and peak at different times into the blood circulation after 
stimulation, it could have been interesting to have an idea of the levels and the kinectics of 
these different mediators to better characterize the inflammatory response following tiger snake 
envenomation.  
 
Blood has been collected in citrated tubes prior to plasma production, which could 
increase IL-6 levels. Nevertheless, citrated tubes were used for all IL-6 blood samples taken. A 
storage at -80°C was made for a maximum of 6 months in order to fulfill storage conditions 
that should not influence our results (Kenis et al. 2002).  
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3.5. Conclusion 
 
This study showed evidence of a systemic inflammatory response occurring on dogs after 
tiger snake envenomation, with the increase of a systemic inflammation marker, the 
interleukin-6.  
 
There was a wide disparity between animals for IL-6 values, which indicates the 
existence of different effects following inflammation of affected animals. Unfortunately, there 
is no study in which a reference range was calculated for IL-6 in dogs. Thus, any increase in 
IL-6 levels was easily recognized and showed evidence of systemic inflammatory response for 
numerous dogs at all various times of blood sample collection. 
 
 No clinical or biological correlation could be made with the studied animals that had the 
highest levels of IL-6. No correlation could be made either between delayed antivenom 
administration or antivenom posology and the increase of IL-6 levels. Pyrogenic reactions did 
not seem to be related to the inflammatory response noticed.  
 
This systemic inflammatory response was highly influenced by delay after envenomation 
and may be even more important after antivenom administration. As antivenom is generated 
from hyperimmune IgG serum, it was previously supposed that antibodies to antivenom might 
participate to the induction of the inflammatory response. 
 
 The increased IL-6 levels after antivenom administration could be consistent with the 
time required to elaborate IL-6 in response to the venom. However, an exacerbation of the 
venom induced inflammatory response by the antivenom itself could not be excluded. An 
attenuation of this inflammatory response may be exploited as a new therapeutic avenue.  
 
This study has some limitations such as a limited number of cases, limited hematological 
and biochemical number of analysis, and the fact that only one marker of the systemic 
inflammatory response (IL-6) have been studied. 
 
Moreover, there is a serious lack of prospective studies on the use of anti-inflammatory 
medicine on dogs, especially regarding tiger snake envenomation. Considering the 
inflammatory response following tiger snake envenomation, it is suggested that the use of anti-
inflammatory therapy in tiger snake envenomation should further be investigated. 
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TITLE: INFLAMMATORY RESPONSE TO NATURALLY OCCURING TIGER SNAKE 
ENVENOMATION IN DOGS, WITH A SPECIAL EMPHASIS ON IL-6  
 
ABSTRACT: 
  
Tiger snakes are the most common snake species implicated in dogs’ snake envenomation in Australia. 
Clinical signs, biochemical and haematological parameters have been studied but the systemic inflammatory 
response to snakebite in dogs is poorly documented. Antivenom administration could further trigger a venom 
induced inflammatory response.  
Ten dogs presented at the University of Melbourne Veterinary Hospital (UMVH) for snake envenomation were 
enrolled in the study. Clinical signs, snakebite data and clinicopathological parameters were recorded. An 
inflammatory marker, interleukin-6 (IL-6), was determined in dog plasma at different times after admission.  
Snakebite caused mild clinical and biochemical signs and variable degrees of coagulopathy. IL-6 was 
indictable for all control cases. For the affected dogs, IL-6 levels widely ranges from 0 pg/mL to 260 pg/mL. IL-6 
concentration was markedly influenced by time and was significantly increased after antivenom administration.  
A systemic inflammatory response naturally occurs in dogs envenomed by tiger snake, possibly exacerbated by 
antivenom administration. Further clinical research including a larger population and additional inflammatory 
markers is warranted to better understand the inflammatory response to snakebite in dogs and to consider new 
therapeutic avenue.  
 
 
KEYWORDS: Interleukin-6, Envenomation, Tiger snake, Elapid, Dog, Immune response, Inflammation 
 
 
 
 
 
TITRE: LA REPONSE INFLAMMATOIRE SYTEMIQUE DES CHIENS SUITE AUX 
ENVENIMATIONS NATURELLES PAR LE SERPENT TIGRE. Etude particulière de l’interleukine-6. 
 
RESUME: 
 
 Le serpent tigre est l’espèce de serpent la plus fréquemment rencontrée en Australie. Bien que certaines études 
aient publié des résultats sur les signes cliniques et les paramètres biochimiques et hématologiques les plus 
fréquents, il existe très peu de données bibliographiques sur la réponse inflammatoire suite aux morsures 
ophidiennes, et plus particulièrement en ce qui concerne cette espèce de serpent. L’administration d’antivenin 
pourrait potentiellement exacerber la réponse inflammatoire induite par le venin lui-même. 
 Dix chiens admis à l’Hôpital Universitaire Vétérinaire de Melbourne suite à une envenimation ophidienne ont 
été inclus dans l’étude. L’anamnèse, les commémoratifs, les signes cliniques, et certains paramètres biochimiques 
et hématologiques ont été enregistrés. Nous avons quantifié l’interleukine-6 (IL-6) plasmatique, marqueur de 
l’inflammation, grâce au kit quantikine standard, à différents temps après admission.  
 Les morsures ophidiennes par des serpents tigres sont à l’origine de signes cliniques et biochimiques modérés 
ainsi que de troubles de la coagulation d’intensité variable. L’IL-6 plasmatique était indétectable chez tous les 
chiens témoins. Chez les chiens envenimés, les concentrations plasmatiques en IL-6 variaient fortement en 
fonction des individus, avec des valeurs extrêmes comprises entre 0 à 260 pg/mL. La concentration en IL-6 était 
significativement plus élevée après l’administration d’antivenin par rapport à l'admission et aux cas témoins.  
 Une réponse inflammatoire systémique est présente chez les chiens envenimés par des serpents tigres et une 
exacerbation de cette réponse immunitaire par l’antivenin ne peut être exclue. D’autres études portant sur un plus 
grand nombre de chien et incluant d’autres marqueurs de l’inflammation seraient souhaitables afin de mieux 
caractériser la réponse inflammatoire systémique des chiens aux morsures par des serpents tigres et d’adapter le 
traitement. 
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